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3 
ABSTRACT 
 
Ischaemia reperfusion injury (IR-injury) occurs when blood supply to a certain area of the 
body is blocked, and is subsequently followed by reperfusion. During the period of 
ischaemia, tissue is damaged as a result of lack of oxygen. Rapid reperfusion is mandatory, 
but unfortunately causes damage in addition to the damage induced by ischaemia alone.  
While a prolonged period of ischaemia is harmful to the bodily tissue, short periods of 
ischaemia interspersed with short bouts of reperfusion have protective effects. This 
mechanism is called ischaemic preconditioning (IPC). In this thesis, the impact of co-
morbidity and age on IR-injury and IPC are explored. Moreover, the possible role of IPC to 
enhance exercise performance is investigated. Finally an attempt is made to understand the 
interchangeable effects of IPC and exercise performance in the prevention of IR-injury.  
Using the brachial artery endothelial function as a surrogate marker, first the consequences 
of IR-injury in both young and older individuals on endothelial function were studied. It was 
also assessed whether IPC could prevent endothelial IR-injury. It was found that endothelial 
function in both groups declined, when IR-injury was not preceded with IPC. However, when 
IPC was applied prior to IR-injury, a protective effect was detected in young subjects, but not 
in older participants. In chapter 5, this study was repeated in patients with heart failure, as 
they are at an increased risk for IR-injury. While in both groups a significant decline in 
endothelial function was observed, a much larger decline was established in the heart failure 
group. Moreover, IPC failed to protect against endothelial dysfunction in heart failure 
patients after IR-injury.   
The third study presented in this thesis, focused on the question whether exercise 
performance enhancement during a 5-km time trial was comparable when IPC on the upper 
legs was applied immediately before the time trial versus 24 hours (24-IPC) prior to exercise. 
Interestingly, a significant and strong correlation was found in finish time between acute IPC 
and 24-IPC, suggesting comparable effects of IPC and 24-IPC on exercise performance. In a 
follow-up study, it was determined whether local IPC applied on the upper arm, or remote 
IPC applied on the legs, would lead to an improved maximum incremental arm crank 
exercise test in individuals with a complete spinal cord lesion. The main finding was that 
upper arm IPC led to an increased performance enhancement, whilst remote IPC (stimulus 
below the lesion) did not lead to any significant differences. These studies help to inform the 
best or most practical application of IPC in daily life situations. 
Some previous work has suggested that exercise may resemble some of the effects of IPC. 
More specifically, acute exercise might possess the same protective effects against 
ischaemia-reperfusion injury as IPC. Therefore, in young healthy individuals it was studied, 
whether an acute bout of endurance or interval exercise is able to protect against brachial 
endothelial IR-injury. It was established that interval exercise prevented endothelial 
dysfunction after an IR stimulus, while no protective effect of endurance exercise was found. 
It was concluded that interval exercise, but not endurance exercise, prevented endothelial 
dysfunction after an ischaemic period.  
In conclusion, this thesis provides further evidence for the protective effects of (remote) IPC, 
both on the prevention of endothelial IR-injury as well as improvement in exercise 
performance. However, effects may depend on the protocol and population studied.  
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General introduction  
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Ischaemic heart disease remains the world’s leading cause of death [1]. When an artery is 
blocked, immediate reperfusion of this artery is mandatory, as prolonged periods of lack of 
oxygen supply will lead to severe cellular damage. However, reperfusion itself also leads to a 
series of adverse events, which are potentially even more lethal to the affected tissue then 
ischaemia alone [2]. The negative consequences of a prolonged period of ischaemia followed 
with reperfusion are referred to as IR-injury, and first described by Jennings et al. [3]. 
While a prolonged period of ischaemia is potentially lethal, short and repeated bouts of 
ischaemia can exert protective effects when applied prior to IR-injury [4]. This intervention is 
termed IPC, and has been subject of several investigations [5]. The effects of IPC are not 
simply restricted to the tissue that was directly exposed to the repeated bouts of ischaemia, 
which means that organs remote to the ischaemic challenge are protected when IPC is 
applied [6]. In addition, IPC is known to exert its effects acutely up to three hours, where 
after it reappears after 24 hours for approximately 48-72 hours [7, 8]. The ability of IPC to 
exert effects in remote organs or tissues, as well as the ability to benefit of IPC well after the 
application, makes IPC an attractive and potentially relevant intervention [9]. 
The general aims of this thesis were twofold. Part 1 relates to the uncertainty regarding the 
efficacy of IPC in specific groups. First, it was studied whether and how cardiovascular risk 
factors and/or disease affect IR-injury and the protective effect of IPC. For this purpose, 
older humans and patients with heart failure in vivo were included (Chapters 4 and 5). We 
hypothesised that both, older age and heart failure, are associated with greater IR-injury and 
diminished protectiveness from IPC, as preclinical studies have shown attenuated responses 
of the ageing heart or in patients with different types of co-morbidities after application of 
IPC [10, 11]. To examine the impact of IR-injury the endothelial function of the brachial 
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artery was assessed before and after IR-injury of the forearm, and presented as a surrogate 
marker of IR-injury.  
A translation of IPC-like strategies to the clinical arena is often disappointing [11], to date 
there remains a lot of uncertainty regarding the potent effects of IPC and pharmacological 
preconditioning in preclinical research in specific groups [12]. As most studies are performed 
in (young) animals, one may question whether a typical patient also benefits from IPC. The 
majority of patients confronted with cardiovascular disease are of older age, as ageing is a 
major risk factor for developing cardiovascular disease [13]. Therefore, in Chapter 4, the 
impact of older age was examined, on the protective effect of IPC on endothelial IR-injury in 
humans in vivo. 
 
Patients with heart failure have a poor prognosis and have an increased risk for adverse 
cardiovascular events and are therefore a key-target for IPC-application [14]. Whilst IPC may 
be an effective approach, the effectiveness of IPC in heart failure is also debated. Little is 
known whether these patients can benefit from this intervention as research in this typical 
group is lacking [15].  In chapter 5, an in vivo study is presented, in compared the protective 
effects of IPC between heart failure patients and their age-matched controls were 
compared. In both groups, the magnitude of endothelial IR-injury and the ability of IPC to 
reduce these possible adverse effects were examined. 
 
Part 2 relates to the interchangeable effects of IPC and exercise. First, a number of studies 
suggest that IPC is an effective intervention to enhance exercise performance, as first 
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described by de Groot et al. [16]. Moreover, another recent study has found some 
preliminary evidence for the effectiveness of acute exercise to prevent the myocardium 
against IR-injury in animals [17]. It was concluded that exercise might has similar 
preconditioning effects as IPC to prevent the negative consequences of IR-injury.   Therefore, 
our second general aim is to study the relationship between IPC and exercise in more detail 
(chapters 6, 7 and 8). It was hypothesised that exercise has potential preconditioning effects 
but that the effect may differ between different modes of exercise. More specifically, it was 
hypothesised that interval exercise (given the remarkable similarities with the repeated 
periods of ischaemia in IPC) has stronger preconditioning effects than endurance exercise. In 
addition, potential of IPC to enhance exercise performance was further explored and an 
attempt was being made to study the related mechanisms.  
Studies exploring the potential of IPC to enhance exercise have typically applied IPC in the 1-
2 hours preceding the exercise event, which is in line with most (pre)clinical work on IPC that 
have demonstrated that the cardioprotective effects are present up to 1-3 h after 
application of IPC. Interestingly, the cardioprotective effects of IPC reappear after 24-h, 
which is referred to as the second window of protection (SWOP) [5]. Whether a SWOP is also 
present in relation to the benefits for exercise performance is currently unknown. Such an 
effect could improve practical application of IPC before an exercise event. Therefore, in 
chapter 6 it was examined whether the effects of IPC on performance enhancement during a 
5-km running trial are similar to the effects when IPC is applied 24-h before the exercise test.  
Studies have shown the ability of IPC to enhance exercise performance in healthy humans, 
predominantly exercise involving the lower limbs. It is for example described that IPC can 
enhance both cycling and running exercise [16, 18]. Subjects with a spinal cord injury are 
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restricted to upper limb exercise. Therefore, in chapter 7 the impact of IPC on upper limb 
arm crank exercise performance in spinal cord injured individuals was examined. In addition, 
it was studied whether IPC has remote effects on upper limb arm crank exercise 
performance by application of IPC on the legs preceding exercise, as this has never been 
studied in relation to exercise before.  
Some recent studies suggested that exercise may have preconditioning effects, which are 
suggested to be similar as observed after the application of IPC [17, 19]. These observations 
raise the question whether some types of exercise might have similar effects as IPC, 
especially since some types of exercise (such as interval exercise) share the characteristic 
repeated exposure to short bouts of ischaemia like in IPC. Therefore, in chapter 8 a study 
was conducted, in which we explored whether exercise can prevent endothelial damage 
after prolonged ischaemia and reperfusion injury. As different types of exercise might lead 
to different outcomes, it was also examined whether different types of exercise possess 
similar preconditioning effects.  The protective effects of moderate endurance exercise and 
high intensity interval in young, healthy subjects were compared on the ability to prevent 
endothelial IR-injury  
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Cardiovascular disease  
Cardiovascular disease (CVD) is the leading cause of death in Europe, and still responsible for 
over 4 million deaths per year, i.e. close to half of all deaths in Europe and 40% in the 
European Union [20]. The annual cost of CVD is estimated to be €169 billion a year in the 
European Union [21].   
Although health care has been improved remarkably in the last few decades and death rates 
have consistently fallen since the early 1960s, there are still a large number of people that 
suffer from coronary heart disease and its consequences. It is for example estimated that in 
the Netherlands alone, 730.000 persons are diagnosed with coronary heart disease [22]. 
Heart failure is commonly diagnosed, in a further 120.000 individuals. Due to the ageing 
population in the Netherlands, it has been estimated that these numbers will rise to 200.000 
in the coming decade [23]. 
Determinants of cardiovascular disease 
In understanding the development of cardiovascular disease, several studies have correlated 
the presence of behavioural factors and subject characteristics (such as biomarkers) to the 
future presence of cardiovascular disease. Classic behavioural risk factors associated with 
the development of CVD are tobacco smoking, physical inactivity, unhealthy diets and 
harmful use of alcohol. Indeed, it is estimated that for example in the UK, more than 20,000 
deaths each year from cardiovascular disease can be attributed to smoking [24]. Non-
modifiable risk factors include sex, ethnic origin and family history, whilst ageing is the most 
important non-modifiable risk factor. Prevalence of CVD increases dramatically with age, 
which is demonstrated to be independent of other cardiovascular risk factors. Not only the 
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prevalence of CVD, but also the morbidity and mortality caused by CVD increases 
exponentially with advancing age [25, 26], with the incidence of myocardial infarction 
doubling between the ages of 45 to 65 [27].  
Already In the 1950s, Morris et al. [28] reported that active bus workers and postmen 
demonstrated a 50% lower event rate from coronary artery disease in comparison to 
colleagues who were physically less active. [28]. Ever since, much research has shown the 
benefits of a physical active lifestyle, while leaving the question on adopting the optimal 
strategy still open for debate. In general, it is now widely accepted that higher fitness level 
and physical activity patterns are beneficial for the prevention of CVD [29, 30]. Although 
these traditional modifiable and non-modifiable risk factors explain the development of CVD 
to a large extent, other unknown factors act as important mediators in the development of 
CVD. For example, approximately 41% of the risk reduction associated with exercise cannot 
be explained by established traditional risk factors [31]. To explain this ‘risk factor gap’, 
Green et al. proposed an important role for the vascular endothelium [32], which plays a 
crucial role in the regulation of vascular tone and in the adaptations of blood vessel 
structure. The endothelium produces numerous paracrine hormones, including nitric oxide 
(NO), which are anti-atherogenic. Endothelial dysfunction precedes and predicts the 
development of atherosclerotic disease and interventions of known cardiovascular benefit 
improve endothelial function. Indeed, Halcox et al. [33] demonstrated that systemic 
endothelial function was associated with progression of preclinical carotid arterial disease 
over a 6-year period and was more closely related to changes in carotid intima-media 
thickness than conventional risk factors [33].  Accordingly, coronary and peripheral 
endothelial dysfunction are independent predictors for cardiovascular events, and 
improvement in endothelial function improves prognosis [34]. Therefore endothelial 
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dysfunction can be considered as an early and integral manifestation of vascular disease and 
improvement in endothelial function should have a significant impact on CV risk [32].  
 
Ischaemic reperfusion injury  
When an artery is blocked, immediate reperfusion of this artery is mandatory, as prolonged 
periods of lack of oxygen supply will lead to severe cellular damage. Consequences of 
depriving an organ of its blood supply have long been recognised as the critical factor in the 
clinical outcome. However, reperfusion itself also leads to a series of adverse events, which 
are potentially even more lethal to the affected tissue then ischaemia alone [35]. For 
example, the histological changes of injury after 3 hour of liver or intestinal ischaemia 
followed by 1 hour of reperfusion are far worse than the changes observed after 4 hour of 
ischaemia alone [36, 37]. The injury of body tissue after restoration of blood flow following 
an ischaemic period is called ischaemic reperfusion injury (IR-injury) and can occur in a 
variety of clinical settings, including reperfusion after thrombolytic therapy, coronary 
angioplasty, organ transplantation, aortic cross-clamping or cardiopulmonary bypass [35]. It 
is believed that tissue damage caused by reperfusion injury has important clinical 
implications, because IR-injury provides clinicians with an opportunity to intervene with 
cardioprotective drugs or other measures that eventually (partly) prevent tissue damage due 
to IR-injury [38].  
The combined lethal effect of ischaemia and reperfusion were first described for the 
myocardium in the early 1960s by Jennings and his co-workers [3]. They reported cell-
swelling, contracture of myofibrils, disruption of the sarcolemma, and the appearance of 
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intramitochondrial calcium phosphate particles [3, 39]. After this landmark study, many 
others have performed comparable experiments to confirm and further understand the 
mechanisms of the detrimental impact of reperfusion after a period of ischaemia in humans 
and animals [39].  
 
Pathophysiology of ischaemic reperfusion injury 
Human body cells tightly regulate cell volume and composition of intracellular and 
extracellular compartments. Of special importance is the balance of different ions between 
the intracellular and extracellular environment. This balance is complex, in that both active 
and passive transport take place. Passive transport of ions across the cell membrane is 
regulated by processes like osmosis and is contingent on the balance between cations and 
anions. Active transport is of special importance, because this allows ions to move against 
their gradient across the cell membrane. Intracellular solute composition differs from the 
extracellular fluid in both volume as well as chemical and electrical potential. These 
differences are essential for a cell to maintain adequate function (Table 1). 
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TabIe 1. Chemical compositions of extracellular and intracellular fluids (adopted from Guyton and 
Hall. textbook of medical physiology 12th edition).  
 Extracellular fluid Intracellular fluid  
   
Na+ 142 mEq/L 10 mEq/L 
K+ 4 mEq/L 140 mEq/L 
Ca2+  2.4 mEq/L 0.0001 mEq/L 
MG2+ 1.2 mEq/L 58 mEq/L 
CL- 103 mEq/L 4 mEq/L 
HCO3- 28 mEq/L 10 mEq/L 
Phosphates 4 mEq/L 75 mEq/L 
SO42- 1 mEq/L 2 mEq/L 
Glucose 90 mg/dl 0 to 20 mg/dl 
Amino Acids 30 mg/dl 200 mg/dl 
Cholesterol/Phospholipids/ 
Neutral fat 
0.5 g/dl 2 to 95 g/dl 
   
Po2 35 mm Hg 20 mm Hg 
PCO2 46 mm Hg 50 mm Hg 
pH 7.4 7.0 
proteins 2 g/dl 16 g/dl 
 
 
Ischaemia  
Intracellular use of both ATP and high-energy phosphates is critical to maintain cellular 
homeostasis [40].  ATP is needed to facilitate active transport, with Na-K pump (or Na,K-
ATPase) being the most important and demanding transport mechanism. During ischaemia, 
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ATP is progressively depleted. The lack of oxygen prevents mitochondrial respiration and 
oxidative phosphorylation, leading to anaerobic glycolysis, thereby causing a gradual 
increase in acidity of the intracellular environment. To buffer the resulting cellular decrease 
in pH, excessive H+ is excreted by accelerated Na+/H+ exchange, which in turn causes 
substantial Na+ inflow into the intracellular space [41].  
Normally, the sodium pump would excrete redundant Na+. However, with the sodium pump 
being ATP-dependent and ATP being depleted during periods of ischaemia, intracellular Na+ 
cannot be removed efficiently during ischaemia. Meanwhile, intracellular depletion of ATP 
also gradually inactivates ATPases, such as the Na-K pump, impacting ATP-dependent Ca2+ 
reuptake, and active Ca2+ excretion. This ultimately results in Ca2+ overload and a subsequent 
reduction in membrane potential [40, 42]. Calcium loading will additionally lead to cellular 
osmotic swelling as a consequence of disturbed homeostatic intra-extracellular balance, and 
any possibility of damage repair during the ischaemic period is prevented by the gradual 
depletion of ATP [43]. Ultimately, the energy compromise and final breakdown of cellular 
components leads to necrotic cell death with rupture of the plasma membrane and 
subsequent inflammatory responses as the tissue is invaded by neutrophils [39].  
 
Reperfusion 
When reperfusion occurs after a prolonged period of ischaemia, oxygen levels are rapidly 
restored and the extracellular pH returns to normal. Despite the restoration of oxygen levels 
and extracellular pH, the intracellular pH is still acidic and this pH gradient facilitates 
extrusion of H+ from the cell in exchange for Na+ [44]. The increased cytosolic Na+ is at least 
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partly extruded in exchange for Ca2+  (reversed function of the Na+-Ca2+ exchanger), thereby 
resulting in a further increase in Ca2+ intracellular levels.  
During reperfusion, mitochondria are re-energised and the rapid delivery of oxygen leads to 
a massive production of reactive oxygen species (ROS), particularly during the initial phase of 
reperfusion [39]. The increase in ROS during ischaemia and reoxygenation is thought to be 
due to damage to electron transport chain components resulting in inefficient transfer of 
electrons, generating superoxide [44]. Consequently, the marked increased production of 
ROS causes further oxidative damage to cellular structures, including the smooth 
endoplasmic reticulum, leading to even more Ca2+ release  [45].  
Another important feature during reperfusion is the opening of the mitochondrial 
permeability transition pore (mPTP), a non-specific, multimeric pore structure spanning the 
mitochondrial inner and outer membranes [43]. mPTP serves as a high-conductance, 
nonselective, voltage-dependent channel and is closed under normal physiologic conditions. 
However, under conditions of cell stress, the formation of the open pore in the inner 
membrane results in the loss of membrane impermeability and rapid collapse of the 
mitochondrial membrane potential [45]. During ischaemia, opening of the mPTP is inhibited 
by the acid cellular environment. However, when pH returns to normal during reperfusion, 
the mPTP is no longer inhibited and therefore reperfusion favours mPTP opening. Opening 
of the mPTP, causes the mitochondria to break down ATP and if unrestrained, will ultimately 
lead to necrotic cell death [43].     
Taken together, although reperfusion after ischaemia is obligatory in order to prevent 
further tissue damage, both ischaemia and reperfusion lead to unfavourable cellular 
processes that provoke greater cellular damage and lead to possible cellular death.  
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Ischaemic reperfusion injury of the endothelium 
The endothelium is the inner layer of a blood vessel and has the ability to secrete different 
vasoactive substances and plays a pivotal role into regulating vascular tone and thereby 
blood flow [46]. Endothelial function is often determined with a non-invasive ultrasound 
technique called ‘flow-mediated dilation’ (FMD), which will be described in the methods 
section into more detail. In healthy blood vessels, the endothelium responds to shear stress, 
with the release of substances (mainly nitric oxide), leading to vasodilation [34]. In general, 
healthy vessels show a larger response, measured as the amount of dilation, as opposed to 
vessels characterised with endothelial dysfunction. Ischaemia-reperfusion refers to a 
prolonged period of ischaemia (when applied as a model in humans typically 15-20 minutes), 
followed by reperfusion of 15-20 minutes.  
After exposure to such IR-injury, a  decline in blood vessel dilation is found [47, 48]. 
Endothelial cells are particularly sensitive to IR, with reperfusion leading to both structural 
and functional damage of the endothelium. Subsequent endothelial injury and swelling due 
to IR can contribute to further ischaemia by impeding blood flow upon reperfusion, which 
has been termed the ‘no-reflow phenomenon’ and is present in the myocardium [49] as well 
as the brain [50].  
This model of 20-minutes of ischaemia leading to impaired endothelial function (but not 
necrosis) is clearly different to the clinical situation of a prolonged (~60 minutes) ischaemia 
of the heart, leading to impaired endothelial function and necrosis. Although much shorter 
in duration of ischaemia than in a myocardial infarction, this model of 20-minutes of forearm 
ischaemia induces reduction in endothelial function. Furthermore, the duration of ischaemia 
may be inferior to the presence of reperfusion. It was for example found in cats, that a 90 
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minutes period of ischaemia alone, did not lead to detectable endothelium damage, while a 
short period of reperfusion after 90  minutes of ischaemia led to attenuated endothelial 
functioning [51]. The negative impact of reperfusion was greater after 20 minutes, than after 
only 2.5 minutes, which is suggestive a pivotal role for (the time of) reperfusion in relation to 
structural and functional damage to the endothelium. Despite the obvious dissimilarities 
with a myocardial infarction, our model is relevant in that it induces endothelial damage due 
to ischaemia-reperfusion injury. 
Ischaemic preconditioning   
Efficacy of treatment of acute ischaemic heart disease has improved the in the last decades. 
Procedures that allow the rapid return of blood flow to the ischaemic zone of the 
myocardium, have led to a 50% reduction in mortality rate [45]. However, as indicated in the 
paragraph above, reperfusion itself also leads to further complications like stunning, cardiac 
arrhythmia and even irreversible cell injury. As described earlier, these complications relate 
for example to the endothelium and the heart, but complications of reperfusion occur in 
every organ when exposed to a prolonged period of ischaemia, such as the brain, the limb 
after knee surgery or the kidney duration transplants [52]. As reperfusion after a period of 
ischaemia is both unavoidable but lethal, scientists have sought for efficient strategies to 
prevent secondary complications after reperfusion therapy.  
A possible protective effect of short bouts of ischaemia preceding actual arterial occlusion 
was first described by cardiologists, who observed that patients reporting angina in the 24 
hours preceding a myocardial infarction show a significantly better outcome in terms of 
development of congestive heart failure, reinfarction, and ultimately, mortality [53]. These 
‘protective’ effects of preceding angina were present despite a paradoxical increase in total 
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time of exposure to ischaemia, and have been referred to as the cardiac warm-up 
phenomenon [54]. 
Murry et al. [4] were the first to actually describe and demonstrate such an effective 
strategy in an experimental animal model. In a dog, the left anterior descending artery was 
occluded (4 times 5 minutes) interspersed with 5 minutes of reperfusion periods where after 
the same artery was occluded for 40 minutes. After the intervention, they found a significant 
reduction in infarction size compared to the control animals, suggesting a protective effect 
on the heart muscle cells.  This intervention has been infinitely repeated in similar 
experiments afterwards, and is termed IPC [44].  In general, IPC is defined as an increased 
tolerance to ischaemia and reperfusion induced by a previous (series of) sub-lethal periods 
of ischaemia. Indeed, such procedures can reduce infarct size by up to 75%, which indicates 
the importance and potency of prevention of IR-injury in the clinical management of 
ischaemic insults [39]. After the first experiments performed in cardiac tissue, many others 
have investigated the impact of IPC in IR-injury on different organ sites. These studies have 
shown IPC to be effective in different organ sites, like the liver, brain, vascular endothelium 
and skeletal muscle [55-58].  
Most studies use occlusion periods of 5 minutes, interspersed with 5 minutes of reperfusion, 
which is repeated 3-4 times.  Although much more variations are possible within this 
protocol, only a few studies have tried to determine whether different protocols lead to 
differences (in the magnitude) of the infarct-sparing effect [59, 60]. In addition, most studies 
are performed in animals, leading to significant inter-species bias, as animals tend to show 
differences between species in response after application of IPC [5]. For example, studies 
using rats of pigs found that the strength of the stimulus was related to the infarction size of 
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the heart [61, 62], while no differences were found in rabbits and dogs [5]. Also in the 
human cardiac tissue, no differences were found in relation to the strength of the stimulus 
[63].  As to date, there is still uncertainty about the optimal protocol to induce maximal 
protection since almost all studies use a  protocol in which 3-4 cycles of 5 minutes of 
occlusion are used.    
  
 
 
 
 
 
Figure 1. Adopted from Yellon et al. [39]. This figure shows the hypothetical effect of myocardial damage after ischaemia 
with and without reperfusion and with and without cardioprotection which may be realised with ischaemic preconditioning.  
At the top bar in yellow, lethal myocardial injury is shown after ischaemia without subsequent reperfusion. The importance 
of reperfusion after an ischaemic period is shown in the middle (blue), leading to a 40% reduction in cardiac damage. 
However, cardioprotection can reduce the harmful effects of Ischaemic reperfusion injury to a large extent as is shown at the 
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bottom in red with another reduction of 25% . Protection against the negative consequences of ischaemic reperfusion injury 
is therefore mandatory, as it can significantly reduce tissue damage to a large extend and thus improve clinical outcome 
 
Physiology of ischaemic preconditioning 
The mechanisms of IPC are not fully understood. However, currently there are some well-
accepted theories used to explain the protective effect of IPC.  When considering 
preconditioning, it is useful to think in terms of triggers, mediators, memory and end-
effectors.  
 
Triggers 
Triggers are released during the short periods of ischaemia and carry the signal for ischaemia 
protection. They are the first step in this complicated signal cascade. Some of the best 
described ‘key triggers’, which are important in starting the IPC signal are adenosine, 
bradykinin and opioids [5, 64] (Figure 2).  As can be depicted from figure 2, other important 
triggers are the reactive oxygen species (ROS). While large amounts of ROS are harmful for 
the cellular components, smaller numbers of ROS can induce IPC, commonly referred to as 
the oxygen paradox. Also norepinephrine is a well-known IPC trigger, while the role of NO is 
still debated regarding classical IPC.  It is interesting to note that blockade of a single 
receptor type only raises the ischaemic threshold instead of completely blocking it [5]. This 
implies that different triggers act together, or the presence of a redundancy in systems, in 
order to bring the cell in a protective phenotype. 
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Mediators and end-effectors  
Mediators are the interconnection between the triggers that start the preconditioning 
cascade, and the end-effectors which are responsible for getting a cell in the preconditioning 
state.  Extracellular signals, surpass the cellular plasma membrane and multiple signal 
transductions pathways converge finally on the mitochondria, which have an important 
lethal function during IR-injury. These pathways either preserve ATP synthesis or prevent the 
onset of mPTP formation [45]. The exact signal transduction pathways have been studied 
extensively. These studies established that the protein kinase C (PKC) exerts an important 
role as a mediator during IPC.  PKC can be either directly activated by adenosine and 
indirectly via bradykinin and opioid peptides and therefore serves as an intermediate in the 
signal cascade.  
An important end-effector leading to early protection after preconditioning is the ATP-
sensitive potassium channel (Katp channel). While the exact mechanism is still debated, 
opening of this channel very likely works as both a trigger and an end-effector of 
preconditioning. While early evidence favoured the role of sarcolemma Katp channels [65], 
latter studies have revealed a possible and far more important role for the mitochondrial 
inner membrane Katp channels [66].  
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Figure 2. Adopted from Yellon et al [5]. A proposed scheme for classical ischaemic preconditioning, in which bradykinin, 
opioids, adenosine and free radicals are able to trigger protection via distinct pathways which finally converge on the 
mitochondrion.  
 
Remote preconditioning 
In addition to the effects of IPC that prevent local cellular injury in the area that was directly 
exposed to the IPC stimulus, studies have also revealed a beneficial effect of similar 
magnitude of IPC on remote regions. This indicates that tissues that were not directly 
exposed to ischaemia are as equally protected against prolonged ischaemia as the tissue 
directly exposed to the IPC stimulus. This phenomenon is commonly referred to as remote 
preconditioning (RIPC) and was first described first by Przyklenk and her group [6]. They 
demonstrated that brief preconditioning occlusions of the circumflex artery also limit infarct 
size from subsequent sustained occlusion of the left anterior descending artery in the dog 
heart [6, 64]. Moreover, the remote protective effects are also present when IPC was 
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applied to a different organ, rather than a different area of the target organ, as shown in 
figure 3. For example, McClanahan, reported  renal ischaemia to be protective in 
preconditioning the heart in a rabbit model [67]. This study was followed by numerous 
(animal) studies providing additional evidence that IPC of an organ results in protective 
effects of other organs not directly exposed to the IPC stimulus [68]. 
The favourable effects of RIPC are of great value in clinical practice, as it allows for the 
application of IPC to an extremity (i.e. arm or leg) to reduce IR-injury of an affected organ 
site that is not directly accessible, like for example the heart or brain tissue. Indeed, 
Kharbanda et al. [48] examined endothelial IR-injury of the forearm before and after IPC 
applied to the contra-lateral arm. They demonstrated that IPC completely abolished the 
negative effects of IR-injury when IPC was applied to the uni- as well as the contra-lateral 
limb compared to IR-injury without IPC. In addition, they demonstrated in a pig animal 
model that IPC performed in a lower limb significantly reduced myocardial infarction size 
after 40 minutes of coronary occlusion compared to a control condition. Subsequently, 
others have shown that RIPC is effective in different mammals and on different organ sites, 
with several studies observing that ischaemic events in the brain adapt cardiac tissue to 
ischaemia [69], or that renal artery occlusion is as effective as direct myocardial IPC in 
reducing infarct size [67, 69, 70]. 
 
25 
 
Figure 3. Adopted from Hausenloy et al. As depicted in the figure, ischemic preconditioning functions remotely, with 
potential beneficial effects on many organs [71] 
 
Delayed ischaemic preconditioning  
In 1993, two independent groups, reported that the protective effect of ischaemic 
preconditioning reappears after 24 hours and can last up to 72 hours [7, 72]. This SWOP, 
may be somewhat less powerful than the early protection, but can still significantly reduce 
infarct size by 50% [7]. Although both classical and delayed protection largely share common 
signalling pathways, several essential differences are present, with the synthesis of new 
proteins being the most striking one [64].  The autocoid factors that trigger classical IPC, are 
also responsible for the protection seen during the SWOP. Again, adenosine is one of the 
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important initiators of protection, since pharmacological blockade of adenosine receptors 
completely abolished the SWOP [8]. Also Bradykinin and ROS are known to have important 
trigger functions [45]. One major difference between the early and late protection relates to 
the role of NO as an essential trigger during the late phase of protection, while its role during 
the early phase is still a matter of debate. Via eNOS-derived NO and superoxide, 
peroxynitrite anion is formed, which in turn activates PKC. DNA microarray studies have 
revealed that preconditioning changes the gene expression pattern in rat hearts, which 
suggest that complex cellular mechanisms are involved in the evolution of late 
preconditioning [45, 73].  
 
Ageing and Ischaemic preconditioning   
A strong negative predictor of recovery from myocardial infarction in humans is older age 
[74]. Although IR-induced myocardial injury can occur in people of all ages, the risk of 
experiencing an IR insult increases with age, with the greatest risk of IR-injury occurring in 
both men and women over the age of 60 [75]. Despite the potent effects of RIPC and 
pharmacological preconditioning in preclinical research, translation of these strategies to the 
clinical area is often disappointing [76]. This may relate to the inclusion of young and healthy 
animals in preclinical studies, whereas application of IPC in the clinical setting typically 
relates to the older patients with co-morbidities. A potential explanation for the detrimental 
effect of advanced age for the development (and consequences) of cardiovascular disease 
may relate to changes in the magnitude of IR-injury and the potential of IPC to prevent this 
effect. For example, ageing affects cardiomyocytes, which undergo complex changes that 
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finally result in loss of contractile function and loss of endogenous protection against 
irreversible injury [25].  
Studies in older animals, suggest that the protective effects of IPC are attenuated in ageing 
hearts [77-79] or brain [80], although data is conflicting [81, 82].  Another study using human 
biomaterial performed with isolated arterial trabeculae from elderly patients, found that IPC 
has no beneficial effect on the functional recovery after stimulated IR [83]. It must be 
emphasised that no previous study in humans has examined the direct impact of ageing of 
the efficacy of IPC in vivo. One possible explanation for the reduced efficacy of IPC might 
relate to the mitochondrion, where an age-dependent unfavourable increase in ROS occurs 
[84].  Whereas low amounts of ROS function as signalling molecules and are essential for 
cardioprotective signalling cascades, high amounts of ROS are detrimental as described 
earlier [25]. The higher amounts of ROS are both caused by enhanced ROS formation and a 
decreased age-dependent antioxidant capacity which collectively leads to oxidative stress 
induces mitochondrial dysfunction [85, 86]. 
Decreased bioavailability of NO, measured either with FMD or as plasma nitrite 
concentration, is another important hallmark of ageing [87]. NO functions as a potent 
vasodilator, but also as an important cellular signalling molecule during the SWOP. Other 
suggested responsible mechanisms for the age-related decline in protectiveness of IPC are 
the decrease of norepinephrine to IPC stimulus [88], impaired PKC translocation in response 
to IPC [89] and an enhanced dephosphorylation by protein phosphates [90, 91].  
As ageing highly influences the impact of IR-injury and the protection afforded by IPC, the 
use of animals as an appropriate model for ageing is debated. Although some studies have 
used older animals, most have used young animals, which raises the question of whether 
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these young animals reflect the same pathophysiological changes during their relatively 
short lifespan as seen with the ageing process in humans. Abete [92] stated that, while 
pathophysiological modifications occurring with age are not dichotomous but progressive, 
the effect of IPC may gradually reduce with increasing age.  It is therefore almost impossible 
to study a progressive ageing model in animals and therefore in vivo studies performed in 
humans are necessary.   
DeVan et al. [47] conducted a study in humans in which they measured endothelial function 
before and after IR-injury in young and middle-aged subjects to gain insight into the primary 
effects of ageing. They found a greater magnitude and delayed recovery from endothelial IR-
injury indicating the unfavourable effects of ageing. Interestingly, habitual exercise in the 
elderly provided partial protection against the endothelium IR-injury, possibly as a result of 
an increased NO-bioavailability related to better physical fitness. The efficacy of IPC to 
prevent or attenuate IR-injury was not explored (in this study) and is topic of chapter 4 of 
this thesis.    
 
Efficacy of IPC in clinical groups 
Although IPC has been proven to be effective in reducing IR-injury to a large extent, in 
clinical practice some practical considerations arise when IPC is applied [93]. As described 
earlier, most events happen in elderly and IPC related interventions are still not efficient in 
reducing IR-injury induced tissue damage. Another important factor that may contribute to 
impaired efficacy of IPC may relate to chronic diseases, like heart failure and diabetes [40]. 
Patients with heart failure are at increased risk of both fatal and nonfatal major adverse 
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cardiovascular events [94]. In heart failure, an increased rate of cardiovascular death in post-
infarcted failing heart suggests that endogenous protective mechanisms against IR-injury 
might be lost or attenuated by the ongoing disease [45]. Indeed, heart failure is 
characterised by a variety of morphological alterations in G-proteins and protein kinase 
activation which might impact on the signal transduction cascade of preconditioning [45].  
These changes suggest that patients with chronic (cardiovascular) disease are especially at 
risk but with limited effectiveness of IPC.  
Interestingly, animal studies show some conflicting data, stressing again the need for human 
in vivo research. A previous study in animals found that HF is associated with an increased 
injury of cardiomyocytes after IR-injury [95], which may relate to the larger risk for cardiac 
events in HF. In comparison, another animal study found an attenuated protective effect of 
IPC against IR-injury in the failing rabbit heart muscle [96]. However, to date, no previous 
studies have examined the impact of HF on IR-injury or whether HF alters the 
cardioprotective effects of IPC seen in healthy humans. This will be topic of research in 
chapter 5 of this thesis. 
 
Ischaemic preconditioning and exercise   
Green et al. postulated that the traditional risk factors can only explain up to 60% of the 
exercise-induced improvement in CHD risk reduction and that therefore other unknown 
mechanism must be responsible for these favourable adaptations [32]. One possible 
explanation for the benefits of exercise (training) might relate to a positive effect of exercise 
(training) on IR-injury and/or IPC, especially since both exercise and IPC can be characterised 
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by repeated exposure to short periods of (local) ischaemia. Recent studies have found 
preliminary evidence from cross-sectional comparisons between highly trained subjects and 
their sedentary peers that exercise training is associated with a reduced endothelial IR-injury 
[47, 97]. These effects may partly contribute to the protective effects of exercise training. 
More importantly, this observation raises the question as to whether exercise training has 
preconditioning effects on the vasculature that eventually contribute to the lower 
endothelial IR injury in trained subjects. Another important hallmark of exercise relates to 
different types of exercise training causing different effects, with high-intensity interval 
training leading to superior effects on physical fitness and the vasculature compared to 
‘traditional’ moderate-intensity exercise [98, 99].   
Interestingly, a recent study from Michelsen and co-workers [17] provided some first 
preliminary evidence that (high-intensity) exercise has IPC-like effects on the protection of 
tissue against prolonged ischaemia [100]. They found that high-intensity interval running 
exercise (4 X 2-min) and ischaemic preconditioning (4x5-min) in humans, followed by blood 
withdrawal and perfusion through isolated rabbit hearts, were similarly able to reduce 
infarct size induced by ligation [100]. These authors concluded that high-intensity exercise 
preconditioning elicits cardioprotection through a humoral mediated mechanism, similar to 
that of ischaemic preconditioning. Whether acute bouts of exercise possess the ability to 
prevent endothelial IR injury in humans in vivo is currently unknown. This will be subject of 
research in chapter 8 of this thesis. 
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Ischaemic preconditioning and exercise performance 
The potential benefits of IPC may be present beyond the ‘traditional’ area of cardiology, 
especially given the apparent similarities that exercise and IPC share. In exercise 
performance, the ultimate goal for all elite and professional athletes is to improve 
performance. De Groot et al. [16] were the first to test the hypothesis that application of IPC 
might be an effective, non-harmful and legal technique to increase performance [16]. They 
postulated that elevated levels of adenosine and Katp channels related improvement of 
oxygen and substrate delivery after IPC might positively influence exercise performance. This 
study showed, for the first time, that ischaemic preconditioning improves maximal 
performance in humans. In fifteen healthy subjects, a significant increase in maximal oxygen 
consumption and maximal power output was established, which suggested that ischaemic 
preconditioning was capable of augmenting performance.  Others have also shown the 
beneficial impact of IPC on maximal performance [101, 102]. More recently, Bailey et al. 
found that repeated IPC of the lower limbs prior to a 5 km trial preserved endothelial 
function of the brachial artery, whereas in the control (no IPC) running group endothelial 
function significantly decreased after exercise [103]. IPC may therefore operate through 
improvements in vascular function, which regulate blood flow to remove and transport 
lactate for uptake and utilization. It is indeed known that IPC improves muscular blood flow 
through intramuscular ATP-sensitive potassium channels and adenosine levels [64]. Shortly 
after this first study published by Bailey et al., the same group showed that IPC  improves 
performance during a 5 km trial [104]. In addition, they also showed that overall increase in 
blood lactate during submaximal exercise was lower when exercise was preceded by IPC 
[104]. These results suggest that IPC may act as an effective tool to improve exercise 
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performance in elite athletes, although the exact underlying mechanisms of this effect 
remain unclear.  
In conclusion, recent studies have revealed positive effects of IPC on exercise performance, 
but underlying mechanisms are poorly understood. It is for example, currently unknown 
whether IPC applied to the non-exercising muscles (i.e. remote IPC) is equally effective as IPC 
of the active muscles. Another issue relates to the timing of the IPC stimulus (first vs. second 
window), which is of special importance for an athlete when applying IPC. This thesis will 
address the question of whether acute and delayed IPC have potential benefit for exercise 
performance in chapter 6 and chapter 7. 
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3 
General methods 
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Methods applied in this thesis:  
Brachial artery endothelial ischaemia-reperfusion injury  
Brachial artery endothelial function. To assess endothelial ischaemia-reperfusion injury (and 
the ability of IPC to attenuate this effect), we make use of assessment of the brachial artery 
endothelial function. For this purpose, brachial artery diameter and blood flow velocity were 
determined by using non-invasive echo-Doppler equipment. Subjects rested in a supine 
position with the right arm extended.  Brachial endothelial (dys)function was measured with 
flow-mediated dilation (FMD). For the assessment of FMD, a rapid inflation/deflation 
pneumatic cuff (E10 rapid cuff inflator, Hokanson, USA) was placed around the right arm 
distal to the olecranon process to provide an ischaemic stimulus distal from the brachial 
artery to provoke vasodilation and subsequent shear stress. The right arm was extended to 
the side and positioned at heart level and was supported with towels to provide a stable 
position for recordings. A 10-MHz multifrequency linear array probe attached to a high-
resolution ultrasound machine was used to perform imaging (T3000, Terason, Aloka, UK). 
The brachial artery was imaged in the distal third of the upper arm. Ultrasound parameters 
were set to optimize longitudinal B-mode images of the luminal-arterial wall interface. A 
continuous Doppler velocity assessment was obtained simultaneously and data were 
collected using the lowest possible insonation angle (always <60°), which did not vary during 
each study. After a resting period of at least 15 minutes, 1 minute of baseline recording of 
the arterial diameter and blood flow velocity was performed. Subsequently, the occlusion 
cuff was inflated to 220 mmHg for 5 minutes. Arterial diameter and blood flow velocity 
recordings were restarted at least 30 seconds before cuff deflation and continued for at least 
3 minutes after deflation [34].  
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In order the minimise variance between measurements, assessments were performed by an 
experienced researcher (Dick Thijssen), who has performed >75 studies related to these 
measurements with the FMD technique.  
 
Brachial artery ischaemia reperfusion (IR).  IR-injury was either induced by a 5-minute 
ischaemic handgrip exercise stimulus followed by 15 minutes of reperfusion, or by a 20-
minute ischaemic period caused by cuff occlusion of the upper arm. The ischaemic handgrip 
was performed at 30% of the maximal voluntary contraction. This protocol leads to a (near) 
maximal ischaemic stimulus and peak reactive hyperaemia [105]. This protocol of prolonged 
ischaemia, followed by reperfusion, is repeatedly found to result in an immediate decrease 
in brachial artery FMD [106-108]. The transient decrease in FMD is believed to reflect IR-
induced endothelial dysfunction, a finding supported by studies that successfully prevented 
this decline in FMD by well-established pharmacological (i.e. statins and physical (i.e. 
ischaemic preconditioning [109, 110]) interventions that protect against IR-injury. This 
method is safe and frequently used. Previous studies from various groups found this 
protocol to result in an immediate decrease in brachial artery FMD [106-108], which is 
believed to reflect IR-induced endothelial dysfunction.  As such, studies have typically 
adopted this model to examine IR-injury in conduit arteries. It is worthy of note that brachial 
artery FMD correlates well with coronary artery endothelial function in humans [111], and 
predicts the extent and severity of coronary atherosclerosis.  
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Ischaemic preconditioning 
IPC was applied proximal on the upper arms, or proximal on the legs using a rapid 
inflation/deflation pneumatic cuff, with either 3 or 4 cycles of 5-minute of  cuff inflation to 
220 mmHg. This IPC-protocol is based on previous studies that have reported a protective 
effect of this stimulus in the heart or peripheral tissues [4, 110, 112-114], with putative 
mechanisms for protection related to the sympathetic nervous system and the production of 
reactive oxygen species [107, 109, 110]. 
Although IPC has been studied extensively, the most effective protocol is still a matter of 
debate [5, 115]. In our studies, a protocol with 3 of 4 cycles of 5 minutes occlusion was 
adopted, as this has been used by many others and has been proven to be effective in 
studying the brachial artery endothelium [48]. While other protocols with more cycles, or a 
longer duration of temporary ischaemia or reperfusion could be potentially more effective, 
this was not one of our aims, and we therefore adhered to well-known protocol which has 
been by others.  
 
 
Brachial artery diameter and blood flow analysis  
Analysis of the brachial artery diameter was performed using custom-designed edge-
detection and wall-tracking software, which is independent of investigator bias [116]. 
Analyses were performed by the author of this thesis and supervised by an experienced 
researcher.  Baseline data were calculated across the 1-minute preceding cuff inflation. 
Following cuff deflation, peak diameter was automatically detected according to an 
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algorithm as described in detail elsewhere [117]. Within-subject reproducibility of the FMD 
using this semi-automated software has a coefficient of variation of 6.7-10.5% [118]. Post-
deflation shear rate data, derived from velocity and diameter measures, were used to 
calculate the shear rate area-under-the-curve (SRAUC).  
A recent study described that inadequate scaling for FMD would be present if the upper 
confidence limit of the regression slope of the relationship between logarithmically 
transformed base diameter and peak diameter is less than one [119].  In such an event, 
FMD% may not be an appropriate measure to estimate endothelial function. Therefore, we 
repeated the analysis for FMD in chapter 4 and chapter 5, using the allometric modelling 
solution [119].  
 
 
Near-infrared spectroscopy 
Near-infrared spectroscopy (NIRS) was used to measure local oxygenation in the lower limb 
tissue during exercise by assessing regional concentration changes in oxyhaemoglobin 
(O2Hb) and deoxyhaemoglobin (HHb) using a continuous-wave near-infrared 
spectrophotometer (OXYMON, Artinis Medical Systems, the Netherlands). The NIRS optodes 
were positioned on the right thigh, twelve centimetres proximal to the fibular head, on the 
vastus lateralis muscle parallel to the long axis of the muscle. NIRS measurements were 
performed continuously. An inter-optode distance of 35 mm was used, resulting in a 
penetration depth of approximately 15-20 mm [120]. Briefly, this technique is based on the 
relative transparency of tissue for light in the near infrared region and on the changes in O2-
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dependent absorption of haemoglobin and myoglobin. As one cannot distinguish between 
myoglobin and haemoglobin, the combined effect of these two substances are studied.  
The changes in absorption measured by NIRS are converted into estimates of concentration 
changes of O2Hb and HHb, while no absolute values of flow can be obtained. The sum of 
O2Hb and HHb reflects changes in blood volume, represented by the total haemoglobin 
signal (tHb). In addition, it is difficult to differentiate with NIRS between skin blood flow and 
muscle blood flow [121]. Therefore, we use NIRS mostly as an observational measurement in 
order to detect patters during acute exercise.   
 
 
Incremental cycling test 
Subjects completed an incremental exercise test on a stationary ergometer (Lode Excalibur, 
Groningen, The Netherlands) to determine VO2max in ml/O2/kg/min; maximum workload in 
wattage (W) and maximum heart rate (HR). Exercise was performed in a temperature 
controlled room (19°C). Oxygen uptake was measured continuously by analysing the expired 
ventilation with a continuous gas analyser (COSMED Quark CPET, Pavona di Albano, Italy), 
calibrated to known reference standards. Dependent on sex and expected fitness level, 
workload was increased every minute with 20 or 25 W. Workload increased every minute 
until volitional exhaustion, typically demonstrated by an inability to cycle at 60-70 
revolutions per minutes. HR was measured continuously with a 12-lead ECG. BP was 
obtained every three minutes to monitor subjects’ health (data not reported). Blood lactate 
level was measured with a finger stick ((Lactate Pro LT-1710, Arkray) before and within 2 
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minutes after the test was finished. All exercise tests were performed under supervision of a 
laboratory technician and a physician. All tests included in our study met at least 3 out of 4 
most often used quality assessment points: ±10 beats/min of the predicted maximum HR 
(208-age*0.7), levelling off VO2 (<150 mlO2 during last minute), post-exercise RER >1.1, and 
post-exercise lactate of >8.0 mmol/L [122].  
 
Incremental arm crank test 
Incremental maximal test. An incremental exercise test was performed on an arm crank 
ergometer (Lode, Groningen, The Netherlands). The arm crank axis was positioned at 
shoulder height of the subject, while straps and wheel blockers were used to keep the 
wheelchair in position. The positioning of the wheelchair in relation to the arm crank was 
recorded and kept the same among the 3 testing days. The arm crank was configured to a 10 
W protocol, starting at a power output of 10 W which increased by 10 W per minute until 
voluntary exhaustion. Subjects were instructed to keep cadence between 60 and 80 rpm, 
and exercise was terminated if subjects were unable to maintain the cadence >60 rpm. 
Exercise was performed in a temperature-controlled room (19°C). Oxygen uptake was 
measured continuously by analysing the expired ventilation with a continuous gas analyser 
(COSMED Quark CPET, Pavona di Albano, Italy), while HR was measured continuously with a 
Polar chest band (Polar RS800, Polar Electro Oy, Finland).  
 
5 km running trial 
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In chapter 6, we used a 5 km running trial in order to assess performance after application of 
IPC or SHAM. A potential improved performance was measured as a decrease in total time 
needed for the 5 km trial. In order to keep environmental circumstances identical, the 5 km 
running trial was performed on an indoor treadmill, while keeping climate conditions similar 
between the tests. During the trial, subjects could chose to increase or decrease speed, but 
were blinded for speed, time and HR and were only informed about total distance covered. 
We chose to perform 3 familiarization sessions for each individual, since a minimum of at 
least one is described by Laursen et al.  [123] 
Ethics 
All individuals, studied in chapter 4, 5, 6, 7 and 8, provided informed consent to participate 
and all these study were approved by the ethics committee of the Radboud University 
Nijmegen Medical Centre.  
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INTRODUCTION 
Despite major advances in prevention and treatment, ischaemic cardiovascular disease 
remain the leading cause of morbidity and mortality worldwide. Current treatment for acute 
ischaemic events in heart, brain or kidney is timely reperfusion of the occluded artery. 
However, as explained earlier in chapter 2, reperfusion of the ischaemic tissue itself will also 
induce injury, commonly referred to as ischaemia–reperfusion (IR)-injury [39]. 
Endothelial cells are particularly sensitive to IR, with reperfusion leading to both structural 
and functional damage of the endothelium, as described in chapter 2. Subsequent 
endothelial injury and swelling due to IR can contribute to further ischaemia by impeding 
blood flow upon reperfusion, which has been termed the ‘no-reflow phenomenon’ and is 
present in the myocardium [49] as well as the brain [50]. Recent evidence support a central 
role for the nitric oxide (NO)-pathway in IR-induced endothelial dysfunction, as 
supplementation of tetrahydrobiopterin (BH-4) or L-arginine protects against IR-induced 
endothelial dysfunction in humans [124]. The no-reflow phenomenon is associated with 
worse clinical outcome and increased mortality in patients undergoing percutaneous 
coronary intervention (PCI) [49]. Therefore, novel therapies to limit IR-injury are urgently 
needed. Ischaemic preconditioning (IPC), i.e. repeated preceding short periods of 
ischaemia,[4] is the most powerful strategy to limit IR-injury in vivo [48, 110, 113]. A 
comparable protective effect can be established with remote IPC and pharmacological 
preconditioning [125].  
Despite the potent effects of (remote) IPC and pharmacological preconditioning in preclinical 
research, translation of these strategies to the clinical arena is often disappointing [126]. 
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This may relate to the inclusion of young and healthy animals in preclinical studies, whereas 
application of IPC in the clinical setting typically relates to older patients with co-morbidities. 
Evaluation of the impact of ageing on cardioprotection is therefore prioritised by a recent 
position paper [126]. Animal studies suggest that the protective effects of IPC are attenuated 
or even abolished in ageing hearts [78] or brain [127], although data is conflicting [81]. Also 
in isolated atrial trabeculae from elderly patients, IPC has no beneficial effect on the 
functional recovery after simulated IR [83]. To date, no previous study examined the impact 
of ageing on the protective effects of IPC in humans in vivo. 
Therefore, in this study, the impact of advanced age on the protective effect of IPC on 
endothelial IR-injury in humans in vivo was examined. In line with previous animal data, as 
described in chapter 2, it was hypothesised that advanced age is associated with an 
abolished protective effect of IPC. Since ischaemia and reperfusion cannot be studied safely 
in heart or brain, brachial artery flow-mediated dilation (FMD; i.e. a measure of peripheral 
artery endothelial function) was used before and after ischaemia (20-min) and reperfusion 
(15-min) as described in chapter 3.  
 
METHODS 
Participants 
Fifteen young (20-25 years) and 15 older healthy men (68-79 years) were included in this 
study. All subjects were free of any cardiovascular disease, diabetes mellitus, hypertension 
(diastolic ≥90 and/or systolic blood pressure (BP) ≥140 mmHg) and hypercholesterolaemia 
(total cholesterol ≥6.5 mmol/L). Moreover, (elite) athletes (performing >10 h/week), 
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smokers, obese subjects (BMI ≥30 kg/m2) and those who were taking medication that 
interferes with our primary outcome parameters were also excluded. The study was 
registered at ClinicalTrials.gov (NCT01606410). 
 
Experimental Design 
Subjects attended to our laboratory twice (separated by at least 7 days, with a maximum of 
28 days). Brachial artery endothelial function was measured with flow-mediated dilation 
(FMD) in the right arm. Brachial artery FMD was measured before and after 20 minutes of 
arm ischaemia and 15 minutes of reperfusion as described in more detail in chapter 3. FMD 
was assessed before and after IR-injury is performed, with or without a preceding ischaemic 
preconditioning stimulus [114]. IPC was performed as 3 cycles of 5-minute occlusion of the 
right upper arm followed by 5-minutes of deflation.  
  
Measurements 
Before each experiment, participants refrained from food ingestion ≥6 hours, caffeine and 
products with high levels of vitamin C intake ≥18 hours, and from strenuous physical activity 
≥24 hours. Subjects were tested at the same time of day to prevent diurnal variation in FMD 
response. All measurements were performed in a temperature-controlled room (22.5°C) and 
using recent guidelines of FMD [34], as described in more detail in chapter 3.    
IR-injury. The rapid inflation/deflation pneumatic cuff was positioned proximally around the 
upper arm to provide an occlusion for 20 minutes, so that the brachial artery was within the 
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ischaemic zone and was exposed to IR. The cuff was inflated for 20 minutes to 220 mmHg, 
which was followed by 15 minutes of reperfusion.  
 
Brachial artery diameter and blood flow analysis 
Analysis of the brachial artery diameter was performed using custom-designed edge-
detection and wall-tracking software as described in chapter 3.  
 
Statistical analysis 
All data were analysed using the Statistical Package for the Social Sciences (SPSS, version 16). 
Data are presented as mean±SD unless stated otherwise. Baseline parameters were 
compared by paired t-tests, whilst baseline characteristics between groups were compared 
using an unpaired Student’s t-test. In order to evaluate the effect of IPC on the impact of IR 
on FMD, the differences between the FMD before and after IR were calculated. These 
differences were then analysed with a linear mixed model analysis with random factor 
subject and fixed factors age group, IPC and the interaction age group*IPC. In an additional 
analysis, baseline characteristics were added as covariates (i.e. BMI, BP, cholesterol, and 
glucose). In a similar way, we also evaluated the impact of preconditioning within the age 
groups, using a mixed model analysis with random factor subject and fixed factor IPC. 
To assess potential confounding by shear rate, which differed between our samples of young 
and elderly volunteers, we also examined the relation between the SRAUC and the change in 
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FMD after IR using a Pearson’s correlation coefficient. The level of statistical significance was 
set at 0.05. 
 
RESULTS 
Baseline characteristics are presented in Table 1. Compared to young men, older men 
demonstrated a higher BMI, systolic BP, total cholesterol, and glucose levels, whilst no 
differences between young and older men were found for body mass, height, diastolic BP, 
and HDL-cholesterol. All values were within the normal range.  
Table 1: Subject characteristics in healthy young (n=15) and older men (n=15)(mean±SD). 
Variable Young men  Older men  P-value 
Age(yrs) 22±1 72±4 <0.001 
Body weight(kg) 76±10 81±9 0.20 
Heigth(cm) 180±7 177±6 0.29 
BMI(kg/m2) 23.4±2.5 25.5±2.5 0.03 
Systolic blood pressure(mmHg) 119±8 128±9 0.007 
Diastolic blood pressure(mmHg) 77±7 76±5 0.54 
Cholesterol(mmol/L) 4.4±0.9 5.2±0.8 0.018 
Triglycerides(mmol/L) 0.9±0.5 1.2±0.3 0.052 
LDL-cholesterol(mmol/L) 2.7±0.7 3.4±0.6 0.005 
HDL-cholesterol(mmol/L) 1.3±0.3 1.2±0.3 0.48 
Glucose(mmol/L) 4.5±0.3 4.9±0.4 0.006 
BMI; body mass index, LDL; low-density lipoprotein, HDL; high-density lipoprotein 
IR and IPC: young men 
There were no significant differences in baseline brachial artery diameter, brachial artery 
FMD (absolute (FMDmm) or relative change (FMD%) from baseline), time-to-peak or SRAUC 
between measurement days (all P>0.05). In young men, FMD% decreased significantly after 
IR (Figure 1). When IR was preceded by IPC, this decrease in FMD was abolished (change 
from baseline, IPC vs. control: P=0.01). Also when FMD was presented as the absolute 
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change in mm, we found that the decrease in FMDmm after IR was abolished when 
preceded by IPC (change from baseline, IPC vs. control: P=0.03, Table 2).  
We found no impact of IR (neither with or without IPC) on the time-to-peak diameter, whilst 
IR was associated with an increase in baseline diameter and decrease in SRAUC (Table 2). The 
change in SRAUC after IR-injury was similar between the control- and IPC-condition, whilst a 
significant interaction effect was found for the change in diameter (change from baseline, 
IPC vs. control: P=0.04). We found no significant relation between SRAUC and the change in 
FMD after IR (r=0.16, P=0.57). 
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FIGURE 1. Brachial artery flow-mediated dilation before (baseline, black bars) and after ischaemia-reperfusion (Post IR, 
white bars) under control conditions (IR) and when preceded by ischaemic preconditioning (IR+IPC) in healthy young (A, 
n=15) and older men (B, n=15). A mixed model analysis revealed a statistically significant difference between the age 
groups (P=0.04).  Error bars represent SE.  
 
IR and IPC: older men 
There were no significant differences in baseline brachial artery diameter, brachial artery 
FMD (in mm or in %), time-to-peak or SRAUC between measurement days (all P>0.05). At 
baseline, older men demonstrated a significantly lower FMD% and FMDmm compared to 
young men (both P=0.001). Older men also demonstrated a significantly larger brachial 
artery resting diameter (P=0.02), and a longer time-to-peak (P=0.04) and a lower SRAUC 
(P=0.003).  
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IR resulted in a significant decrease in brachial artery FMD in older men (Figure 1). When IR 
was preceded by IPC, however, a similar decrease in FMD was observed (IR*IPC interaction: 
P=0.62). Also when FMD was presented as the absolute change in mm, we found a 
comparable decrease in FMDmm after IR between both conditions in older men (change 
from baseline, IPC vs. control: P=0.52, Table 2). The primary endpoint of the study was the 
difference in IPC-induced protection between the young and elderly subjects. IPC-induced 
protection appeared to be significantly reduced in the elderly patients (P=0.04). After 
correction for the differences in baseline characteristics (BMI, BP, cholesterol, and glucose), 
the size of the difference in protection did not change, but the P-value increased to 0.07. 
In addition, IPC did not alter the time-to-peak diameter, whilst IR was associated with an 
increase in resting diameter and decrease in  SRAUC in older men (Table 2). The changes in 
resting diameter and SRAUC were similar between both conditions (Table 2). We found no 
significant relation between baseline SRAUC and the change in FMD after IR in the older 
subjects or in the pooled data set (r=0.09 and P=0.75, r=0.24 and P=0.21, respectively), 
excluding relevant bias by differences in shear rate (SRAUC).  
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Table 2: Brachial artery characteristics before and after ischaemia-reperfusion (IR) when preceded by a control intervention or ischaemic preconditioning 
(IPC) in healthy young and older men (n=15). Data is presented as mean±SD. 
 
Young men 
Control IPC P-values 
Baseline  IR Baseline  IR IPC vs control1 Older vs young2 
FDM (%) 6.4±2.7 4.4±1.8 5.9±2.3 5.6±2.5 0.01  
FMD (mm) 0.25±0.09 0.19±0.07 0.23±0.08 0.22±0.08 0.03  
Diameter (mm) 3.9±0. 5 4.3±0.6 4.0±0.6 4.2±0.7 0.04  
Time-to-peak diameter (s) 43±10 38±14 41±10 34±9 0.77  
SRAUC (s, 103) 29.5±9.4 22.8±8.0 28.6±5.3 23.2±8.9 0.59  
 
Older men 
      
FDM (%) 3.5±1.7 2.5±1.0 3.7±2.1 2.2±1.1 0.62 0.04 
FMD (mm) 0.15±0.05 0.11±0.04 0.16±0.08 0.10±0.05 0.52 0.06 
Diameter (mm) 4.4±0.5 4.8±0.5 4.4±0.5 4.8±0.7 0.83 0.36 
Time to peak diameter (s) 55±19 51±21 58±26 54±30 0.97 0.87 
SRAUC (s, 103) 20.5±5.3 14.9±7.4 20.7±8.3 16.0±9.2 0.67 0.85 
1P-value for difference in change from baseline (IPC vs control), 2P-value for difference in effect of  IPC on change from baseline (young vs old) 
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DISCUSSION 
The purpose of this study was to examine the impact of advanced age on the protective 
effect of IPC on endothelial IR-injury in humans in vivo. First, it was found that IR impairs 
brachial artery endothelial function, which is in agreement with various other studies as 
described in more detail in chapter 2. Second, IR-induced endothelial dysfunction in young 
men can be prevented when preceded by 3 cycles of 5-minute ischaemia of the upper-arm 
prior to the ischaemic event. More importantly, it was demonstrated for the first time in 
humans that older age is associated with an abolished effect of IPC to protect against IR-
induced endothelial dysfunction in the brachial artery.  
IR-induced endothelial dysfunction is of particular importance as this contributes to impeded 
blood flow upon reperfusion, commonly referred to as the ‘no-reflow phenomenon [49].  The 
presence of the ‘no-reflow phenomenon’ in the coronary arteries is frequently reported in 
patients with an acute myocardial infarction. In this study, we adopted a model of IR-injury 
using prolonged ischaemia of the forearm. As demonstrated in various, independent 
laboratories [110, 128], the model of forearm IR-stress applied in the current study results in 
a significant decrease in brachial artery endothelial function in young as well as in older men. 
This indicates that our model is valid to detect IR-induced endothelial dysfunction. 
Moreover, in this similar model, IPC prevents against endothelial dysfunction after IR in 
healthy, young to middle-aged volunteers [110, 113]. In this study, we confirm these 
observations in a group of young, healthy men.  
The main finding of our study is that  the protective effect of IPC on brachial artery 
endothelial IR-injury was abolished in older men. This observation is in agreement with some 
previous suggestions in animals [78, 129] and a human ex vivo study on isolated atrial 
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trabeculae [83]. However, this latter study failed to correct for potential confounders, such 
as medication and cardiovascular risk factors. Although some report an age-related decline 
in efficacy of IPC [130, 131], these studies are limited by their use of endpoints which are not 
valid to assess effects of preconditioning (i.e. ST-segment elevation) [125] and the inclusion 
of subjects with cardiovascular disease and risk factors [130, 131]. In our study we included 
only healthy, older subjects without cardiovascular risk factors. Even statistically correcting 
for differences between young and older men in BMI, BP, cholesterol, and glucose did not 
change our major outcomes. More evidence for successfully including a representative 
healthy older population relates to the lower brachial artery FMD, but also a longer time-to-
peak diameter and larger baseline diameter, compared to young subjects. These findings 
confirm previous observations in healthy older men [132]. Taken together, we provide the 
first evidence in a group of healthy older humans that the effect of IPC to prevent IR-induced 
endothelial dysfunction in the forearm is abolished. 
 
Although it was not the purpose, our ‘proof of concept’-study raises the question about the 
potential underlying mechanism. First, the attenuated effect of IPC may relate to an elevated 
threshold for triggering IPC protection rather than a complete loss of IPC to be protective. 
Longer ischaemia and/or increased episodes of ischaemia/reperfusion in the IPC-protocol 
may be necessary in the older population for IPC to be protective, such as previously 
described for diabetes mellitus type 2 [133]. It is demonstrated, primarily based on evidence 
derived from cardiac tissue, that IPC cardioprotection is regulated via different pathways, 
such as the nitric oxide(NO)-pathway, reperfusion injury salvage kinase(RISK)-pathway and 
AMP-activated protein kinase. These pathways converge on mitochondria and prevent 
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opening of the mitochondrial permeability transition pore (mPTP) upon reperfusion and 
subsequent cell death [134]. A recent paper comprehensively discusses the impact of ageing 
on the signalling cascades that seem to contribute to the loss of cardioprotection by IPC in 
the aged heart [25]. Although the mechanisms of IPC-related protection may substantially 
differ between cardiac and vascular sites, ageing seems to result in a decreased protein 
expression and blunted responses of signalling molecules, such as heat shock protein 70 
content, extracellular ligand (e.g. IGF-1 and IL-6), decreased levels of connexin 43 or lower 
expression level of sarcolemmal receptors (e.g. IGF-1 receptor, bradykinin receptors) [25]. 
Also, blunted activation of protein kinases (e.g. ERK1/2, Akt, GSK3beta, or p38) and age-
related mitochondrial changes have been hypothesised to contribute to the age-related loss 
of cardioprotection via IPC [135]. Generally, these suggestions are typically made based on: 
1. the importance of these signalling cascades for cardioprotection by IPC and 2. the impact 
of ageing on these cascades. Taken together, future studies are necessary to elucidate the 
underlying pathways and the potential interacting effects between pathways in humans, but 
also distinguish between cardiac and vascular tissue as the IPC-driven effects may differ 
between vessel sites.  
Limitations. Strengths of this study include the controlled design, inclusion of homogenous 
healthy groups, within-subject comparison regarding the impact of IPC and the use of 
observer-independent analysis. The model that has been used has several limitations. First, 
the impact of IR-injury and IPC in the forearm vasculature was studied  rather than directly in 
the cardiac tissue. The brachial artery was chosen because of earlier described (chapter 3) 
similarities in function with the coronary arteries. Nonetheless, one should take caution 
when extrapolating our findings to other vascular beds, especially since due to ethical 
reasons, we had to choose a relative short period of ischemia in order to attain the IR-injury. 
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Secondly, we did not use an endothelium independent vasodilator, so we cannot exclude 
that the detrimental effect of IR on FMD reflects a reduced sensitivity of the vascular smooth 
muscle cells to nitric oxide. Thirdly, the diameter of the brachial artery did not return to 
baseline after IR. Based on the inverse relation between baseline diameter and FMD [34], 
the increase in diameter may relate to the decrease in FMD. However, the magnitude of 
increase in diameter was consistent across young and older subjects and additional analyses 
corrected for these changes. Therefore, changes in diameter unlikely explain our principle 
findings. Another limitation is the lower SRAUC in the older cohort compared to younger men. 
However, young and older men showed no correlation between SRAUC and the change in 
FMD after IR. Moreover, the changes in SRAUC after IR (with or without IPC), were similar in 
both groups. Therefore, it is unlikely that a difference in SRAUC per se explains our findings. 
Finally, cardiovascular risk factors (e.g. hyperlipidaemia, diabetes, hypertension) are likely to 
interfere with the endogenous cardioprotective effects of IPC in humans [45]. In our study, 
BMI, BP, cholesterol and glucose levels were all within the normal range and none used 
medication known to interfere with these variables. The somewhat higher values in the 
older population may relate to physiological human ageing, which is associated with small, 
but gradual changes in these parameters. Finally, when statistically correcting for these 
parameters, we found a similar effect size of IPC in young and older subjects. Therefore, the 
conclusions drawn based on our observations in this study are valid for a typical, healthy 
cohort of older men. 
Clinical Relevance. Our observation of an abolished effect of IPC raises questions about the 
impact of ageing on ischaemic post- or peri-conditioning; i.e. alternative strategies to 
prevent IR-injury. It is believed that the various methods of ischaemic conditioning share a 
final common pathway that prevents opening of the mPTP [136]. 
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Although speculative, advanced age may therefore also impact upon the efficacy of 
ischaemic peri- or postconditioning as described in chapter 2. However, this requires further 
research in humans and is speculative at this stage. In contrast to traditional IPC, the 
application of remote IPC may be clinically more relevant as the latter procedure can be 
applied to a remote vascular bed. Whether ageing also affects remote IPC is unknown and 
represents a logical extension from our current findings. 
The results from this study demonstrates that brachial artery endothelial ischaemia-
reperfusion injury can be prevented by IPC in young healthy men but not in elderly subjects. 
This finding may have important implications for studies that examine the efficacy of IPC as 
an intervention to prevent endothelial IR-injury and limit cardiac damage in a clinical setting. 
IPC and alternative interventions based on IPC are currently being applied in a large number 
of randomised controlled trials to prevent cardiac IR injury in patients. Compared to 
preclinical studies, application of (remote) IPC in the clinical setting is often disappointing 
[126]. This may relate to the inclusion of healthy, young animals in preclinical studies, whilst 
clinical trials mostly involve elderly (discussed in more detail in the synthesis, chapter 9). Our 
observations, therefore, highlight the importance of first examining the effects of novel 
cardioprotective strategies in older animals before translation is made to humans. Also, the 
impact of age should be considered when examining the effect of interventions that prevent 
or attenuate endothelial dysfunction after IR by including an age-matched control group 
(preferably a one-by-one matching) and/or including age as a potential co-factor in statistical 
analyses.  
The results from this study indicate that IR-injury is more pronounced in the elderly 
population, and that IPC does not protect against IR-injury in the elderly. As discussed in 
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more detail in the synthesis (chapter 9), most work in IPC has been performed in relatively 
young and healthy animals. Therefore, more research in the diseased populations is 
necessary to truly understand the impact of IPC in a relevant population. As the protocol 
used in this chapter has proven to be effective in measuring the consequences of IR-injury 
and IPC in vivo (in a clinically relevant population), this study set-up was used in a  follow-up 
study using patients with heart failure and presented in the following chapter.  
 
 
 
5 
Heart failure is associated with exaggerated endothelial 
ischaemia-reperfusion injury and attenuated effect of 
ischaemic preconditioning 
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INTRODUCTION  
Heart failure (HF) is a major cause of death in developed countries and represents a growing 
public health problem, partly due to the ageing population, and is responsible for an 
increasing proportion of hospital admissions [137]. A potential explanation for the poor 
prognosis of HF patients may relate to an exaggerated ischaemia-reperfusion (IR)-injury in 
HF as demonstrated in rats [95].  Such an increased vulnerability to IR-injury is clinically 
relevant, as this may contribute to worsening of the clinical outcome after a cardiovascular 
event. DeVan and colleagues demonstrated that traditional cardiovascular risk factors, such 
as advanced age, are associated with a greater magnitude and delayed recovery from 
endothelial IR-injury in humans [47]. Also experimental studies suggest that the presence of 
cardiovascular risk factors or disease is associated with exaggerated IR-injury [25, 95, 138], 
although some studies suggest otherwise [139, 140], including our previous work as 
presented in chapter 4. Accordingly, we examined the hypothesis that HF patients 
demonstrate an increased endothelial IR-injury compared to healthy peers in vivo.  
 
Originally described in animals, ischaemic preconditioning (IPC; intermittent episodes of 
nonlethal ischaemia) is a powerful strategy to limit or even prevent IR-injury [4]. As 
described in chapter 3, previous human in vivo studies found that IPC effectively prevents 
endothelial IR-injury. Despite successful pre-clinical studies, clinical trials implementing IPC 
have demonstrated somewhat disappointing results [9], which was partly established in 
chapter 4, as IPC was only effective in young healthy individuals and not in the elderly. 
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Another potential explanation for the lack of clinical effects relates to the interaction 
between the efficacy of IPC and the presence of cardiovascular risk factors or disease. 
Indeed, some preclinical studies provide evidence that HF is associated with an attenuated 
efficacy of IPC to prevent injury [96, 141, 142]. Since no previous study in humans has 
explored this hypothesis, the second aim of the study is to examine the efficacy of IPC to 
prevent or attenuate endothelial IR-injury in patients with HF. To study these questions, we 
examined brachial artery flow-mediated dilation (FMD) before and after ischaemia (induced 
by 5-minute ischaemic handgrip exercise) and reperfusion (15-min) and used the reduction 
in FMD as a well-validated marker of endothelial injury.  
 
 
METHODS 
Participants 
15 subjects with HF (67±10 years, NYHA-class II/III, ejection fraction ≤ 45%) and 15 healthy, 
age- and sex-matched older subjects (65±9 years) were included in this study. HF patients 
were recruited from the Department of Cardiology of the Radboud University Nijmegen 
Medical Centre. Exclusion criteria were set for pre-menopausal women (or women with 
hormone replacement therapy), subjects with diabetes mellitus type 1 or 2, hypertension 
(systolic ≥140 or diastolic ≥90 mmHg), chronic obstructive pulmonary disease and severe 
hepatic or renal insufficiency. Healthy control subjects were free of any chronic disease and 
did not use any type of medication known to interfere with the cardiovascular system. HF 
patients were categorised as New York Heart Association (NYHA) class II/III. Patients were on 
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stable optimised pharmacological therapy for ≥3 months. All subjects signed an informed 
consent and study procedures were approved by the local ethics committee and performed 
according to the Declaration of Helsinki (2000). 
 
Experimental Design 
Subjects attended our laboratory twice (separated by at least 7 days). Brachial artery 
endothelial function was measured with FMD in the right arm. Brachial artery FMD was 
measured before and after IR-injury. IR-injury was induced by a 5-minute ischaemic handgrip 
exercise stimulus followed by 15 minutes of reperfusion. Local ischaemia during handgrip 
exercise was induced with upper arm cuff inflation to 220 mmHg. The assessment of FMD 
before and after IR-injury was performed with or without the preceding ischaemic 
preconditioning stimulus (IPC-intervention). IPC consisted of 3 cycles of 5-minute upper arm 
cuff inflation to 220 mmHg, with 5 minutes reperfusion time after each occlusion.  
 
Measurements 
Body anthropometric data. Body mass (Seca 888 scale, Hamburg, Germany) and height were 
measured to calculate body mass index (in kg/m2). A four-point skin fold thickness 
measurement (biceps, triceps, sub-scapular, supra-iliac) was obtained in order to calculate 
the lean body mass. Waist circumference was measured midway between the lower rib 
margin and iliac crest. Hip circumference was measured at the level of widest circumference 
over greater trochanters. Waist to-hip ratio was calculated as waist circumference divided by 
hip circumference. Resting HR and BP were measured twice in supine position, using a 
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manual sphygmomanometer after 5-min of rest.  Finally, with a finger stitch a small amount 
of blood was collected in order to assess glucose and blood cholesterol levels. 
Flow mediated dilation (FMD). All measurements were performed in a temperature-
controlled room (22.5°C) and using recent guidelines of FMD [34], as described in more 
detail in chapter 3.    
  
Brachial artery diameter and blood flow analysis 
Analysis of the brachial artery diameter was performed using custom-designed edge-
detection and wall-tracking software, as described in chapter 3. 
Statistical analysis 
All data were analysed using the Statistical Package for the Social Sciences (SPSS, version 20). 
Data are presented as mean±SD unless stated otherwise. Baseline characteristics between 
groups were compared using an unpaired Student’s t-test. In order to evaluate the impact of 
IR on endothelial function (measured as FMD) between groups (primary aim), and whether 
IPC can (partially) prevent endothelial IR (secondary aim), we employed a linear mixed 
model analysis. For aim 1, FMD was analysed with random factor subject and 2 fixed factors: 
time (pre versus post) and group (HF versus control). The interaction-effect IR*group was 
used to examine our primary aim (i.e. examine whether IR injury was different between 
groups). To examine whether IPC can prevent the decline in FMD after IR in both groups (i.e. 
secondary aim), we repeated this analysis with the addition of 1 fixed factor: intervention 
(IPC versus control) and explored the interaction IR*group*IPC. When a significant 
interaction-effect was found, we adopted post-hoc analysis to identify differences. As 
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described in chapter 3,  analysis for FMD were repeated using the allometric modelling 
solution [119]. The level of statistical significance was set at 0.05. 
 
RESULTS 
Baseline characteristics are presented in Table 1 and 2. Compared to controls, HF patients 
demonstrated a lower total cholesterol and a higher waist-to-hip ratio, whilst no differences 
between HF patients and controls were found for age, body mass, height, systolic BP, 
diastolic BP, fat percentage and fasting glucose.  
Table 1: Subject characteristics in heart failure (n=15) and healthy, age- and sex-matched 
controls (n=15). Data is presented as mean±SD.  
Variable Heart failure  Controls  P-value 
Age (yrs) 65±9 67±10 0.56 
Sex (male:female) 13:2 11:4  
Body weight (kg) 92±18 82±15 0.13 
Height (cm) 178±8 176±8 0.67 
BMI (kg/m2) 29.2±6.4 26.2±3.5 0.12 
Systolic blood pressure (mmHg) 114±14 121±7 0.08 
Diastolic blood pressure (mmHg) 71±9 77±5 0.05 
Waist-to-hip ratio 1.02±0.09 0.92±0.12 0.02 
Fat percentage (%) 33.2±7.4 29.8±6.2 0.19 
Cholesterol(mmol/L) 4.9±1.1 6.1±1.2 0.01 
Glucose(mmol/L) 4.9±1.4 4.9±0.4 0.98 
BMI; body mass index  
 
 
 
 
 
 
 
 
 
 
 
62 
 
 
 
Table 2: Heart failure patient characteristics (n=15). 
 Heart failure 
Ischaemic / non-ischaemic 12 / 3 
Medication use  
ACE-inhibitors 8 (53 %) 
Angiotensin II receptor antagonists 6 (40%) 
Diuretics 10 (67%) 
β-blockers 15 (100%) 
Coumarin derivatives 7 (47%) 
Statins 8 (53%) 
 
Endothelial IR-injury 
No significant differences between HF patients and healthy controls were found for baseline 
brachial artery diameter, brachial artery FMD (absolute (FMDmm)) or relative change from 
baseline (FMD%), time to peak diameter, or SRAUC (all P>0.05, Table 3). IR resulted in a 
significant increase in resting diameter (Table 3). To control for the potential impact of the 
increase in diameter on FMD%, baseline diameter was included as a co-factor in the 2-factor 
statistical analysis (IR and group). This analysis revealed a significant interaction-effect 
(IR*group: P=0.01, Table 3). Subsequent analysis revealed that IR resulted in a significant 
decrease in brachial artery FMD in HF and controls (P=0.002 and 0.02, respectively, Figure 1). 
However, the magnitude of decrease in FMD after IR was larger in HF patients compared to 
controls (Table 3). Also when FMD was presented as the absolute change (in mm), the 
decrease in FMDmm was significantly larger after IR in HF patients than in controls (Table 3). 
When repeating the analysis for FMD using the allometric scaling approach, including 
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correction for the change in diameter, our initial observations of a larger decline in FMD in 
HF compared to controls after IR were confirmed (Table 3).  
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Table 3: Brachial artery characteristics before and after ischaemia-reperfusion (IR) when preceded by a control intervention or ischaemic 
preconditioning (IPC) in heart failure and controls (n=15).  
 Heart failure Controls Two-way and three-way ANOVA 
Baseline  IR Baseline  IR IR Group IR*Group IPC IR*IPC Group*IR*IPC 
FMD (%) 6.2±3.6 3.3±1.8* 4.9±2.1 4.1±2.0* <0.001 0.79 0.01    
FMD (%), allometrically scaled 6.1±2.4 3.3±2.4* 4.8±2.4 4.0±2.3* <0.001 0.73 0.01    
Diameter baseline (cm) 0.44±0.07 0.46±0.08 0.43±0.06 0.44±0.06 0.006 0.47 0.95    
Absolute FMD (mm) 0.26±0.14 0.15±0.09* 0.21±0.10 0.18±0.10* <0.001 0.77 0.006    
Time-to-peak diameter (s) 51±19 58±29 45±13 48±15 0.299 0.13 0.76    
SRAUC (s, 103) 22.2±8.1 23.0±8.5 22.7±8.9 22.7±1.0 0.74 0.98 0.74    
IPC       
FMD (%) 5.8±2.7 3.7±2.4* 4.2±1.5 4.0±2.0 <0.001 0.52 0.002 0.53 0.20 0.85 
FMD (%), allometrically scaled 5.6±2.2 3.8±2.2* 4.0±2.2 4.1±2.2 <0.001 0.47 0.001 0.50 0.14 0.89 
Diameter baseline (cm) 0.43±0.07 0.46±0.09* 0.42±0.05 0.46±0.06* <0.001 0.65 0.86 0.74 0.15 0.81 
Absolute FMD (mm) 0.24±0.12 0.16±0.10* 0.18±0.07 0.18±0.08 <0.001 0.54 0.001 0.40 0.22 0.93 
Time to peak diameter (s) 55±22 57±26 66±20 54±26 0.93 0.72 0.22 0.04 0.17 0.42 
SRAUC (s, 103) 23.5±1.3 23.9±9.5 21.0±8.6 19.2±7.0 0.92 0.51 0.55 0.54 0.66 0.79 
Data is presented as mean±SD. SRAUC, area under the shear rate curve;  FMD, flow-mediated dilation. 
*Post hoc significantly different from baseline 
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IPC and endothelial IR-injury 
No differences  were found in HF patients or in controls between both testing days for 
baseline brachial artery diameter, brachial artery FMD (absolute (FMDmm)) or relative 
change from baseline (FMD%), time to peak diameter, or SRAUC (all P>0.05, Table 3). In line 
with the analysis above, it was statistically controlled for the potential impact of baseline 
diameter on the FMD%, by including these parameters as a co-factor in the statistical 
analysis. The 3-way ANOVA confirmed the presence of a decrease in brachial artery FMD 
after IR (P<0.001), which is significantly larger in HF patients compared to controls (P=0.01, 
Figure 1). Moreover, IPC did not significantly alter the decrease in FMD (Time*Group*IPC-
interaction: P=0.85). Also when FMD was presented as the absolute change (in mm) or using 
allometric scaling, we found that the decrease in FMD after IR was not changed by IPC (Table 
3). Post-hoc analysis revealed that IPC prevented the decline in FMD after IR in healthy 
controls, whilst IPC showed no effect in heart failure patients (Table 3). 
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FIGURE 1. Brachial artery flow-mediated dilation before (baseline, black bars) and after endothelial ischaemia-reperfusion 
(Post IR, white bars) ischaemia-reperfusion (IR) injury and when preceded by ischaemic preconditioning (IPC + IR-injury) in 
healthy controls (A, n=15) and heart failure patients (B, n=15). A mixed model analysis revealed a statistically larger decline 
in FMD after IR in heart failure compared to controls (P=0.001), whilst IPC did not change the decline in FMD after IR in both 
groups (P=0.87).  Error bars represent SE. *Post hoc significantly different from baseline at P<0.05. #Post hoc significantly 
larger change in FMD than in controls at P<0.05. 
 
 
DISCUSSION 
This study provides a number of novel findings. First, a significantly larger decline in brachial 
artery FMD after IR-injury in HF patients (~46%) compared with their healthy peers (~16%) 
was found. This indicates that in agreement with our hypothesis, HF patients demonstrate 
an exaggerated endothelial injury after IR compared to their healthy controls. Second, we 
found that IR-induced endothelial dysfunction cannot be prevented by ischaemic 
preconditioning in HF patients, a finding that is in line with the observation from chapter 4 in 
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which IR-induces endothelial dysfunction could not be prevented by ischaemic 
preconditioning with older age. Accordingly, the magnitude of decline in FMD after IR-injury 
when preceded with IPC, remains larger in HF patients than in their healthy age- and sex-
matched controls. Therefore, our study revealed that HF is associated with an exaggerated 
decline in endothelial function after IR-injury, whilst IPC failed to protect against this 
decrease. 
 
Endothelial IR-injury 
In agreement with previous work, including chapter 4, it was found that IR-injury induces a 
transient, conduit artery endothelial dysfunction [109, 110]. A novel observation is that HF 
patients demonstrate an exaggerated decline in FMD after IR-injury compared with their 
healthy peers. To date, the impact of HF on IR-injury has only been examined in animal 
studies, which provided conflicting results ranging from an increased [139, 140] to a 
decreased tolerance [25, 95, 138] against prolonged ischaemia. Differences in the ischaemia-
stimulus within and between studies may contribute to these conflicting results. In this 
study, both groups received the same ischaemic stimulus. Moreover, inter-species 
differences or the experimental procedures to induce HF may also have contributed to the 
conflicting results from animal studies. Nonetheless, our study provides support that, in 
humans, HF is associated with an exaggerated decline in endothelial function after 
endothelial IR-injury. 
 
  
68 
Although speculative, the larger decline in FMD in HF patients than controls after IR may 
relate to differences in antioxidative capacity between groups. Endothelial injury after IR is 
caused, at least partially, by excessive production of oxidative stress [143]. Whilst healthy 
individuals have a well-controlled balance between the production of reactive oxygen 
species (ROS) and antioxidative enzymes, patients with HF demonstrate less antioxidative 
capacity, resulting in increased oxidative stress [144, 145].  Nonetheless, our novel 
observations in HF patients warrants future research to better understand the potential 
underlying mechanisms that contribute to the exaggerated IR-injury in HF. 
 
IPC and endothelial IR-injury 
In the previous chapter, it was demonstrated that the well-established protective effects of 
IPC are abolished in healthy older men compared to younger control patients.  In addition, 
the present study provides evidence that the protective effect of IPC to attenuate 
endothelial IR-injury is also abolished in HF patients. This latter observation is in line with 
data from animals, supporting an emerging hypothesis of a reduced efficacy of IPC 
associated with cardiovascular disease or risk factors [9, 45, 141]. For example, a recent 
animal study revealed the inability of preconditioning to protect the old diabetic heart 
against an ischaemic insult [146]. In line with these findings, preclinical studies in patients 
with HF demonstrated an impaired effect of preconditioning to prevent ischaemia-induced 
tissue damage [96, 141, 142]. 
In this chapter, IPC was effective in healthy age-matched controls, which is in contrast to 
chapter 4 in which it was established that IPC was not effective in healthy older humans. 
  
69 
Some important differences between both studies must be highlighted. First, subjects 
included in chapter 4 were somewhat older than chapter 5 (72 years vs 67 years). In 
addition, baseline FMD values were lower in chapter 4, while systolic BP was higher in 
chapter 5 (although still within normal range), suggesting that the older subjects in the 
previous chapter show somewhat impaired vascular function. At the other hand, cholesterol 
levels tended to be somewhat higher in the control group from this study. Finally, the model 
to induce ischaemia-reperfusion injury differed between studies (20-min ischaemia versus 5-
min ischaemic handgrip exercise). Although speculative, these differences may relate to the 
different findings between chapter 4 and 5. 
 
This study supports the detrimental findings on the efficacy of IPC in HF patients. We can 
only speculate about possible mechanisms to explain this finding. Preclinical studies suggest 
that the impaired efficacy of IPC in cardiovascular disease is linked to morphological and 
biochemical alterations, which may impact on signal transduction [45]. For instance, it was 
recently demonstrated that the presence of post-infarction cardiac remodelling is closely 
linked to an abolished effect of IPC [142]. Whilst this finding supports a role for 
morphological changes underlying our findings, others have provided support for 
biochemical alterations in patients with HF. Indeed, IPC in HF failed to induce protein kinase 
C-ε translocation [147], which represents an important step in the protection through 
preconditioning. Finally, mitochondrial defects in the genesis and progression of HF have 
also been proposed to contribute to the diminished effect of IPC. While mitochondria seem 
to serve as end-effectors of IPC, decreased enzyme activities of the electron transport seen 
in failing hearts may potentially negatively impact the efficacy of IPC [45]. 
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Clinical implication. Our finding of a reduced efficacy of IPC in HF patients may have clinical 
implications. Various (non)pharmacological preconditioning interventions are currently 
applied in randomised controlled trials in patients, including those with HF. Despite some 
recent successful studies [112, 148], application of (remote) IPC in the clinical setting in 
general is often disappointing [126]. The increased cardiovascular death rate in post-
infarcted, failing hearts suggests that endogenous protective mechanisms in HF against IR-
injury may be lost or attenuated [45]; a finding which is in line with the present study. 
Possible reasons relate to the inclusion of relatively young animals in preclinical studies with 
a relatively short disease duration, whilst clinical trials mostly involve patient groups such as 
HF (e.g. in heart transplantation) [45]. Therefore the majority of preclinical studies do not 
adequately reflect the clinical setting in which patients are included with lower efficacy of 
IPC. This should be taken into consideration when examining the impact of IPC in clinical 
groups, such as HF. 
  
Limitations. A number of limitations must be discussed. As discussed in chapter 4,  we used 
the endothelium of the forearm as a surrogate marker.  Given the aetiology of HF as a 
disease affecting the heart, studying the heart muscle tissue directly might reveal even more 
pronounced results on the magnitude of IR-injury. Secondly, in contrast to previous studies 
that adopted 15-20 minutes of ischaemia to induce endothelial IR-injury, our study used 5-
min ischaemic handgrip. However, as described earlier, previous work demonstrated that 5-
minutes of ischaemic handgrip exercise induces reperfusion that is at least similar to 15-
minutes of ischaemia. Moreover, FMD decreased in both groups using this protocol. 
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Therefore, this approach is valid to examine endothelial IR-injury. Third, patients in our study 
continued their medication during testing. Continuing medication in HF patients may explain 
why we found no differences in FMD between groups.  Indeed, our FMD-data matches with 
previous studies that included medicated HF patients [149]. We deliberately chose to 
continue (pharmacological) treatment, so that our results would reflect a ‘real life’ situation. 
This approach revealed, despite the intake of drugs with established preconditioning effects 
(i.e. statins), that an exaggerated endothelial IR-injury in HF patients could not be attenuated 
by IPC. These findings raise questions regarding the potential loss of preconditioning effects 
of statins with sustained intake, such as recently highlighted [150]. Finally, we only examined 
a single time-point after IR-injury. This limits insight into a potential difference between 
groups (or between interventions) in the time-course of restoration of FMD after IR injury. 
Such differences in time-course may have provided further insight to better understand our 
findings.   
 
In conclusion, we provide data in humans in vivo that HF is associated with an exaggerated 
damage to the endothelium after an ischaemic insult, which cannot be prevented by IPC. 
These novel findings may contribute to the poor clinical outcome after cardiac injury in HF 
patients, and should be considered when examining the effects of traditional, non-
pharmacological preconditioning in HF patients. This highlights the search for alternative 
protocols or application of IPC that may bypass these limitations, ultimately leading to the 
ability of HF patients (and other populations) to benefit from IPC. In the next chapters, a link 
is made between the effects of exercise and IPC. To explore the possible links between 
exercise and IPC, the next chapter will first explore the effects of IPC on exercise 
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performance. Therefore, in the next chapter, a study is presented, in which both acute and 
24-IPC is investigated in runners performing a 5-km trial. A link between IPC and exercise 
would increase possible strategies to benefit from the cardioprotective, preconditioning 
effects of IPC. 
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Is delayed ischaemic preconditioning as effective on running 
performance during a 5-km time trial as acute IPC? 
JOOST P.H. SEEGER, SILVIE TIMMERS, DANIQUE J.M. PLOEGMAKERS, N.  TIMOTHY CABLE, MARIA T.E. 
HOPMAN, DICK H.J. THIJSSEN. 
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INTRODUCTION  
IPC was originally described as an effective strategy to protect cardiac cells against a 
prolonged period of ischaemia. Most studies therefore have focused on the potential 
cardioprotective abilities, leading to large, multi-centre trials that established the potency of 
IPC to attenuate cardiac damage and improve clinical prognosis [112, 148, 151]. 
Interestingly, IPC is suggested to exert also beneficial effects when applied directly before an 
exercise session.  
 
De Groot et al. were the first to explore the ability of IPC to enhance physical performance 
[16]. They found significant improvement in exercise performance when a maximal cycle test 
was preceded by IPC. Similar findings of performance enhancement were reported by others 
during swimming, running, cycling, rowing and handgrip exercise, [18, 101, 152-155], but not 
all [155-157] (i.e. involving running and cycling). Those studies were mainly designed to 
assess the direct effect of IPC on exercise performance, while the working mechanism of IPC 
on skeletal muscle oxygenation status is less explored.   
 
All previous studies exploring the impact of IPC to exercise performance timed IPC in close 
proximity to the exercise event. This however, imposes practical limitations, as IPC cannot 
always be applied in close proximity to the start of an athletic event. As described in chapter 
2, SWOP can be applied 24-72 hours before an event and may be effective in reducing the 
consequences of IR-injury (just like the benefits described for IPC).These observations raise 
the question whether enhanced performance is also present when IPC is applied 24-72 h 
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prior to the exercise event to match the event with SWOP. Practically, such timing would be 
preferred over the application of IPC immediately before an athletic event.  
 
The primary aim of this study, therefore, was to assess the hypothesis of whether IPC 
applied 24-hours before the running trial (i.e. timed together with the start of the SWOP) is 
equally effective in changing exercise performance compared to the application of IPC 
immediately before a running event in healthy volunteers. Secondly, it was explored 
whether the effect of (24-h) IPC is related to changes in local tissue oxygenation (measured 
with Near-infrared Spectroscopy (NIRS)) of the vastus lateralis muscle during running 
exercise and/or production of lactate at the end of exercise. Such insight may help to better 
understand the potential mechanisms contributing to the exercise benefits of (24-h) IPC in 
humans. 
 
 
METHODS 
Sample size calculation 
The sample size calculation was based on a study performed by Baily et al. [18]. In this study, 
also moderately trained healthy subjects were included and performed a 5-km time trial 
with and without IPC. Bailey et al. found that IPC resulted in a significant decrease of 34 
seconds to cover the 5 km (p<0.05), with a standard deviation of 28 seconds (σ). Therefore, a 
difference in finish time between the IPC and control condition of 30 seconds (d) was 
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considered relevant and realistic in our study population. Furthermore, a power (β) of 90% 
and an alpha (α) of 0.05 was used for the power calculation with the formula (Zα + Zβ )2 x σ2))/ 
d2  with α = 0.05 (two-sided, Zα = 1.96), power = 0.90 (Zβ = 1.65), σ=28 and d=30. According to 
nQuery, a total of 12 subjects is needed to detect a relevant effect of IPC on exercise 
performance.  
 
 
Subjects 
Adopting a randomised, cross-over study, 12 healthy participants volunteered to participate. 
Baseline characteristics are shown in Table 1. Subjects were moderate to well-trained 
amateur runners (Table 1), who exercised at least two hours a week, including a minimum of 
one hour running at moderate-to-high intensity. Older participants (>50 years) were 
excluded as well as subjects with cardiovascular disease or any other chronic disease 
effecting maximal performance as this may affect the efficacy of IPC as shown in chapters 4 
and 5. Prior to participation, subjects were informed about the procedures of the study, but 
not about the rationale of the study to keep subjects naive about the potential effect of IPC 
as well as the timing of IPC. All subjects gave their written informed consent prior to 
participation. This study was approved by the local ethics committee of the Radboud 
University Medical Centre. 
 
Experimental design 
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Subjects visited our laboratory at six different occasions (including 3 familiarization sessions 
to customise to the 5-km time trial), to perform a 5-km time trial on a treadmill. On the first 
day, participants were examined prior to testing by a physician, comprising an assessment of 
an electrocardiography under resting conditions. On all testing days, subjects refrained from 
alcohol, caffeine, tea, chocolate and (intensive) physical exercise for at least 24 h prior to 
testing as these factors may potentially influence exercise performance. Additionally, 
subjects were asked to adopt a similar eating pattern at all days of the measurements. 
Participants were tested at the same time of day to control for diurnal variation and its 
impact on exercise performance [158], while measurements were performed in a 
temperature-controlled testing room with the temperature set at 19ºC. Testing days were 
separated by at least 4 days, in order to prevent possible carry-over effects of the exercise 
bout and/or IPC. 
First, participants performed three familiarization sessions on a treadmill. Participants were 
instructed to run a 5-km time trial on a motorised treadmill (EN-BO Systems, Bonte BV, the 
Netherlands) as fast as possible, while being blinded for time, speed and HR, but not running 
distance. Average group times were 1416 seconds for the first session, 1418 seconds for the 
second session and 1434 seconds for the last familiarisation session. The coefficient of 
variance was calculated between the first and second session (1.8%), and between the first 
and third session (1.6%). When being familiarised with running the 5-km trial, the 
experiment started. In a randomised order, participants received IPC, 24-IPC and SHAM. 
Participants were informed that all interventions, including SHAM, could potentially lead to 
an improved running performance to keep them naive. After the application of IPC, 
participants performed a standardised warm-up, followed by the 5-km time trial. 
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Interventions 
Ischaemic preconditioning (IPC). IPC was performed in the supine position using bilateral 
arterial occlusion [16]. Occlusion cuffs were positioned proximally around the thigh 
(bilaterally) and inflated to 220 mmHg to block arterial inflow for 5 minutes, followed by a 5 
minute deflation. This procedure was repeated 4 times, with each ischaemic episode 
separated by 5 minutes rest. For the IPC intervention, this procedure was started 1 hour 
before the time trial, whilst the procedure was timed exactly 24 hour prior to the time trial 
for the 24-IPC. 
Control intervention (SHAM). The control intervention was performed under the same 
conditions as the intervention test, but this time the cuff was inflated to only 20 mmHg, 
which did not alter the arterial inflow. The Sham intervention was performed directly before 
exercise.  
 
Measurements 
5-km running trial. After the IPC/SHAM-intervention, subjects were seated for 5 minutes. 
Subsequently, subjects performed a 5-minute warm-up followed by another 5 minutes to 
stretch their muscles as preferred, after which the 5-km running time trial was started. The 
5-km running trial was performed on a motorised treadmill. Main outcome parameter was 
finish time (Fisher Scientific, the Netherlands). The speed of the treadmill was set at 11 
km/h, where after participants were allowed to alter running speed, but were kept blinded 
for running speed and running time. Participants were instructed to run 5-km as fast as 
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possible. The only information available to the participants during each time trial was total 
distance covered (m) as to adjust work-output to pace towards the known endpoint. No 
further information/feedback and/or encouragements were provided during the 5-km trial.  
 
Near-infrared Spectroscopy (NIRS)  
NIRS measurements were carried out on the belly of the vastus lateralis muscle 12 cm above 
the fibular head. To ensure the optodes and detector did not move relative to the 
participant’s skin, the device was fixed into position using surgical tape. Quantitative NIRS 
measurements of muscle oxygenation (mVO2) from O2Hb were obtained during exercise and 
subsequently, tissue saturation index (TSI) was calculated as the percentage of O2Hb/O2Mb 
of total Hb and Mb. NIRS is described in more detail in chapter 3. 
Secondary parameters – HR was measured continuously by a Polar chest band (Polar® RS 
800) and recorded every 500m. BP was measured at the right arm before, during and after 
the IPC/SHAM-intervention and after the time trial. Furthermore, a finger capillary blood 
sample (Accutrend® Lactate, Roche Diagnostics, Mannheim, Germany) was taken before and 
after the IPC-/SHAM-intervention, but also after the 5-km time trial to measure blood lactate 
levels. In addition, the rate of perceived exertion was registered on a Borg-scale (6-20) 
during warm up, every 500 m and after the 5-km time trial.  
 
Statistics 
Data is presented as mean ± SD, unless stated otherwise. To examine differences in finish 
time between the interventions, one-way repeated measures ANOVA was used. To examine 
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whether IPC and 24-IPC lead to comparable changes in exercise performance (i.e. primary 
aim of the study), we used a Pearson correlation coefficient to relate changes in finish time 
after IPC versus 24-IPC. Using a 2-way ANOVA, we examined whether changes in TSI, HR, 
pace time and BORG during the time trial (every 500m; ‘time’) differs across the 3 conditions 
(‘intervention’; SHAM vs IPC vs 24-IPC). Differences across the conditions were analysed by 
repeated measures ANOVA. Finally, to investigate which parameters contributed to the 
change in exercise performance after IPC or 24-IPC (i.e. ∆IPC-control, ∆24-IPC–control), a 
stepwise linear regression analysis was performed. Study parameters included in this model 
were presented as the change between IPC versus control or 24-IPC versus control. 
Differences were considered to be statistically significant at P<0.05.  
 
 
RESULTS 
 
Table 1. Baseline characteristics (n = 12). Values are presented as mean ± SD. 
Parameter Mean±Sd 
Male/female 10/2 
Age, years 31±6 
Body mass index, kg/m2 21.8±2.5 
Running time/week, minutes 191±78 
Total running experience, years 9±8 
 
5-km time trial 
No differences in finish time between IPC (1381±112s), 24-IPC (1385±112s) and SHAM 
(1400±105s), (P=0.30, Figure 1A) were found. Also no significant changes were observed 
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when calculating the change in finish time between IPC versus SHAM (-16±39s, P=0.14) or 
24-IPC versus SHAM (-16±58s, P=0.29).  However, when pooling the individual changes in 
finish time after IPC and 24-IPC, a trend was observed for improvement in finish time 
(P=0.10, Figure 1B). Interestingly, a significant positive relation appeared to be present 
between the change in finish time after IPC versus the change after 24-IPC (P=0.016; r=0.677, 
Figure 2). 
 
 
FIGURE 1. Individual presentation (n=12) of the finish time during the SHAM, IPC and 24-IPC intervention (A, in seconds) 
and the change in finish time compared to SHAM after application of IPC or 24-IPC (B, in seconds). A negative value in B 
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relates to a better finish time. Each dot represents a single participant. The horizontal line represents the average, with the 
error bars representing the SE. 
 
 
 
FIGURE 2: Correlation between the individual changes in finish time compared to SHAM after application of IPC (X-axis, in 
seconds) and the change in finish time between SHAM and 24-IPC (Y-axis, in seconds) in our participants (n=12). A negative 
value on both axes relates to a better finish time after IPC or 24-IPC. The dotted line represents the regression line from the 
Pearson’s correlation coefficient 
 
Exercise characteristics 
HR gradually increased during the 5-km time trial, but these increases were similar among 
the different interventions (P=0.63). Pace slightly decreased during the 5-km time trial in the 
three conditions (figure 3), with a significant time*treatment effect for 24-IPC (P=0.016). 
Post-hoc analysis showed that subjects started at a higher pace during the 24-IPC time trial 
and ended with a somewhat lower pace compared to the other two conditions. All 
participants reached a similar level of exertion at the end of the 3 time trials (SHAM: 19 ± 2 
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BORG, IPC: 19 ± 2 BORG, 24-IPC: 19 ± 2 BORG; P=0.60)). Blood lactate levels significantly 
increased after the 5-km time trial, whilst no differences were found among the 3 trials in 
post-exercise lactate levels (SHAM: 6.4 ± 3.1 mmol/l, IPC: 8.0 ± 2.7 mmol/l, 24-IPC: 7.5 ± 2.2 
mmol/l; P=0.30, P=0.24). Finally, TSI, as measured with NIRS on the vastus lateralis muscle, 
showed a rapid decrease in saturation upon the start of the 5-km time trial and remained 
stable thereafter. This time-dependent change was similar among all three conditions 
(P=0.14, Figure 4). 
  
  
84 
 
  
FIGURE 3. A) Average heart rate is shown for each intervention, for every 500 meters (n=12) A similar increase between 
interventions was found (P=0.63).  B) Pacing time is shown for every 500 meters, with the exception of the first 500 meters 
(n-12). Error bars represent SE. Pace slightly decreased during the 5-km time trial in the three conditions (figure 3), with a 
significant time*treatment effect for 24-IPC (P=0.016).  
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FIGURE 4 Tissue saturation index (TSI) derived from the near infra-red spectroscopy measurement on the vastus lateralis 
muscle during the 5-km time trial at 0.5-km intervals in healthy volunteers (n=9). The time trial was preceded by SHAM 
(closed circles), IPC (closed squares) or 24-IPC (closed triangles). Error bars represent SE. 
 
 
Factors predicting change in finish time 
Stepwise linear regression was performed to identify whether exercise characteristics could 
predict the change in finish time after IPC or 24-IPC. Post-exercise blood lactate 
concentration significantly contributed to the change in running time after IPC or 24-IPC 
(R2=0.47, β=-0.687, P=0.007). More specifically, lower post-exercise blood lactate levels after 
IPC or 24-IPC were significantly related to an improvement in finish time.  The number of 
training hours and differences between trials in maximal HR and TSI did not contribute to 
changes in finish time.  
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This is the first study to compare the impact of the application of IPC 24-hours before the 
exercise bout versus IPC immediately before exercise on performance. The following findings 
are presented. Overall, no significant effect of 24-IPC or IPC on exercise performance during 
a 5-km time trial in moderately-to-well trained athletes was found, despite the fact that the 
majority of the participants improved their running performance after IPC or 24-IPC. 
However, a strong and positive relationship existed, between the change in finish time when 
the 5-km trial was preceded by IPC versus 24-IPC. This suggests that, at an individual level, 
24-IPC exerts a comparable effect on exercise performance compared to IPC during a 5-km 
running time trial.  Finally, improvement in finish time was strongly related to a decrease in 
post-exercise blood lactate levels, but not to changes in vastus lateralis muscle oxygenation. 
Taken together, at an individual level, the effect sizes of 24-IPC and IPC during a 5-km time 
trial are strongly related.  
 
No significant effect of IPC on exercise performance was found, which contrast with some 
[16, 18, 101, 152-155], but not all studies [155-157]. Although not significant, the effect size 
found in our study is 1.4% reduction in running time, which corresponds well with other 
studies that reported a 1- 4% improvement in peak workload [16, 152], peak oxygen 
consumption [16], improvement in finish time [18, 101, 154] or prolonged time to 
exhaustion [153, 155]. One potential explanation for the absence of a significant effect is 
that our self-selected exercise protocol resulted in a relatively large variation in running time 
within participants despite three familiarization sessions before the actual start. These types 
of exercise trials are importantly influenced by the athlete’s experience and motivation [159-
162]. As a result, the coefficient of variation of the self-paced 5-km time trial (1.6-1.8%) is 
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somewhat higher than a priori expected.  Moreover, our sample size calculation was based 
on a study performed by Bailey et al. [18], in which participants ran faster and therefore 
showed a relatively larger effect of IPC than in the present study. Consequently, more 
subjects may be necessary to detect differences when adopting the self-paced 5-km time 
trial. In support of this hypothesis, previous work that reported an effect of IPC to improve 
exercise performance, adopted an exercise protocol where subjects performed exercise at 
maximal effort level. Indeed, these previous studies adopted exercise tests that caused 
substantially larger blood lactate concentration (~12-13 mmol/l) [16, 101] compared to our 
protocol (~6-8 mmol/l). Taken together, although we found no significant effect of IPC on 
exercise performance, the effect size of IPC is comparable to previous studies in this field. 
 
The primary aim of our study was to explore whether 24-IPC and IPC would cause 
comparable changes in running time. In agreement with our hypothesis, a strong and 
positive correlation was found between the change in running time after IPC and 24-IPC. In 
other words, subjects who demonstrated an improved running performance after IPC were 
likely to show comparable benefits of 24-IPC. Similarly, those who did not show 
improvement in running time after IPC, also showed no change after 24-IPC. Although our 
study is the first in the literature to demonstrate that IPC and 24-IPC have comparable 
effects on exercise performance, these findings are largely in agreement with previous work 
on IPC and protection of cardiac damage by the SWOP. Previous work on the 
cardioprotective effects of IPC and 24-IPC found comparable protection against prolonged 
ischaemia [163-165], although some data is conflicting [166]. Taken together, our data 
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extends previous work in the area of cardiology, in that the effect of 24-IPC on exercise 
performance is comparable to that observed after IPC. 
 
In an attempt to better understand the underlying mechanisms that contribute to the 
potential effects of IPC and 24-IPC on exercise performance, we explored tissue saturation of 
the vastus lateralis muscle during the time trial. Previous work in animals linked IPC to 
improved muscle oxygenation during exercise as well as after exercise performance in rats 
[167]. Studies that have measured the TSI using NIRS, a measure that reflects the ability of 
tissue to take up oxygen, report a 20% decrease in TSI after IPC relative to control [154, 168]. 
In our study, it was found that IPC and 24-IPC exerted a similar impact on TSI during exercise 
than SHAM [168]. This observation suggests that IPC and 24-IPC did not alter muscle oxygen 
delivery during exercise [169]. This is supported by the regression analysis, which excluded 
the change in TSI induced by IPC or 24-IPC as a potential predictor for a change in running 
time during the 5-km time trial. 
 
An alternative explanation for the underlying mechanisms relates to blood lactate levels 
during exercise. Previous work demonstrated that changes in blood lactate concentration 
and mitochondrial capacity account for 68% of the variation in cycling time trial performance 
[170]. Furthermore, lower blood lactate concentrations at a given workload improves 
endurance exercise in various populations, including in highly trained [165]. These 
observations are somewhat in line with earlier observations from Bailey et al., who 
demonstrated that IPC lowers blood lactate levels during running exercise at submaximal 
intensity [18]. Interestingly, running speed associated with lower blood lactate levels after 
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IPC matched with the running speed of the 5-km time trial [18]. Therefore, our findings 
provide some further support that IPC may enhance exercise performance through changes 
in the lactate pathways. Alternatively, IPC and 24-IPC may enhance mitochondrial function 
[5]. During exercise, contracting skeletal muscles generate free radicals that cause cellular 
damage and impaired mitochondrial function [171]. Since mitochondrial oxidative capacity is 
strongly linked to exercise performance [172], the effects of IPC and 24-IPC may be related 
to the protective effects on mitochondrial function.  
 
Limitations. The correlation we observed between the change in running time after IPC and 
24-IPC may be confounded by the presence of collinearity, as both parameters are 
calculated using the SHAM-running trial. This must be considered when interpreting these 
findings. Although three familiarizations sessions were included prior to testing, the 
relatively high day-to-day variability of 1.6-1.8% in athlete’s performance could have 
influenced our results, especially since the effect size of 1.4 % was somewhat smaller than 
initially anticipated. Interestingly, when all data from IPC and 24-IPC are pooled (n=24), we 
found a trend for a decline in the time trial (P=0.10).   Most limitations of the present study 
relate to the protocol adopted and are discussed in more detail in chapter 3. 
 
Perspectives 
On an individual level, 24-IPC is as effective as acute IPC, which implies that both can be used 
preceding a contest. However, as there are high interindividual differences in response to 
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application of IPC, more research is needed in order to establish the interaction between the 
timing of IPC stimulus and exercise performance during a 5-km time trial.   
In conclusion, our results suggest a small, non-significant effect of IPC and 24-IPC on exercise 
performance during a self-paced 5-km time trial in a group of healthy volunteers. In addition 
we found a strong relation between the effect of IPC versus 24-IPC, which suggests that IPC 
and 24-IPC demonstrate comparable effect sizes (at an individual level), although the results 
could be partly a result of collinearity . Consequently, IPC may be applied before the exercise 
event, which represents a more feasible and practical approach compared to the application 
of IPC immediately before the exercise event. However, based on the results from this study, 
it is too early to advice an individual athlete whether he or she would respond to 24-IPC. In 
order to better understand the effects of 24-IPC, more studies a needed, giving more insight 
into underlying mechanisms that could potentially influence whether someone responds to 
IPC or does not.  
In this study we have investigated whether 24-IPC has got the same ability as acute IPC to 
enhance exercise performance in healthy individuals. Although we did not find a significant 
overall effect, we established that individuals who respond to acute IPC, likely also respond 
to 24-IPC. While this study adds to the current knowledge of research performed in healthy 
individuals, to date there has been no study published in which the effect of IPC on exercise 
performance was explored in clinical populations. This question is specifically relevant, since 
our and other work showed that IPC has reduced efficacy to prevent endothelial ischaemia-
reperfusion injury in clinical populations (see chapters 4-5). Whether the exercise benefits of 
IPC are also reduced in clinical populations is unknown. Therefore, we wanted to know 
whether IPC could also be performed in subjects with a spinal cord lesion (chapter 7). 
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Therefore, in our follow-study, we investigated the effect of IPC and RIPC on performance in 
individuals with a complete spinal cord lesion.  
 
 
 
 
 
7 
 Ischaemic preconditioning improves performance in 
spinal cord injured individuals 
JOOST P.H. SEEGER, JAN T. GROOTHUIS, ILSE VAN NES,  SILVIE TIMMERS, N.  TIMOTHY CABLE, MARIA T.E. 
HOPMAN, DICK H.J. THIJSSEN 
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INTRODUCTION  
IPC has the ability to enhance exercise performance (see chapter 6).  Whilst the mechanisms 
are unclear, studies which have shown that IPC also provides protection of  many organs and 
tissues, including the peripheral vasculature [110] and the skeletal muscle [57]. Studies have 
found that IPC prior to an exercise bout in healthy subjects improved finish time [18, 101], 
power output [102] and lowered lactate accumulation [18], but no change in oxygen 
consumption was found [18, 102, 156]. To date, studies examining the impact of IPC on 
exercise performance have focused exclusively on healthy young (trained) subjects. 
 
Sport participation by spinal cord injured (SCI) individuals is associated with increased 
perceived quality of life and social integration [173, 174] and, as a result, has become 
increasingly popular, also at the competitive level [175]. This coincides with the interest in 
procedures to improve exercise performance in SCI [176].  In line with observations in able-
bodied subjects, it  is hypothesised that IPC will enhance arm crank exercise performance in 
SCI individuals. Therefore, the first aim of this study was to examine the impact of IPC, 
applied to the upper limbs, on exercise duration, maximal workload and maximal oxygen 
consumption during an incremental arm crank exercise test in SCI individuals. 
 
Studies have described that, in addition to the local effects of IPC in the area exposed to 
repeated ischaemia, IPC can also exert beneficial effects in distant, remote areas [6, 177]. 
For example, IPC applied to a single coronary artery also protects a remote vascular bed of 
the myocardium supplied by another artery [6]. Also, IPC applied to another organ, such as 
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the kidney, reduces myocardial infarct size [177]. Subsequently, many others have confirmed 
the presence of RIPC in the protection of prolonged ischaemia [178-180]. Interestingly, a 
recent study provided evidence for improved exercise performance after the application of 
RIPC [153]. Whether RIPC also improves exercise performance in SCI is of special importance, 
since the activation of neural pathways have been suggested to partly explain the effect of 
RIPC [71]. As neural pathways from the legs are interrupted in SCI individuals with a 
complete thoracic lesion, we hypothesize that RIPC has no effect on exercise performance in 
SCI. Our second aim, therefore, was to study the impact of RIPC (i.e. stimulus applied to the 
legs) on exercise performance during an incremental arm crank test in SCI individuals.  
 
METHODS 
Subjects 
12 SCI individuals (1 female) volunteered to participate in this study. All subjects had a 
traumatic motor and sensory complete thoracic spinal cord lesion (T4-T12); AIS A [181], 
except for one who had a motor complete but sensory incomplete lesion (AIS B).  One spinal 
cord lesion originated from surgical removal of a benign tumour (table 1). All individuals 
were free of any cardiovascular disease and were not physically restricted to perform 
strenuous arm-crank exercise. Since older age may impact the efficacy of IPC (chapter 4), we 
selected subjects 18-60 years. Moreover,  based on the results of chapter 5, we expect that 
individuals with a maximum age of 60 years old, do respond to IPC. Subject characteristics 
are summarised in Table 1. Prior to participation, all subjects gave their written informed 
  
94 
consent. The study was performed according to the Declaration of Helsinki (2000) and 
approved by the ethics committee of the Radboud university medical center. 
 
Experimental design 
In this randomised, single-blind, crossover study, subjects visited our laboratory at 3 
different occasions to perform an incremental maximal arm crank exercise test. 
Randomization was done before the first intervention by means of a computer-generated 
randomization list (SPSS, version 22). Testing days were separated by at least 7 days, in order 
to prevent possible carry-over effects.  On the first day, participants were examined prior to 
testing by a physician, including assessment of an electrocardiography under resting 
conditions. Prior to all testing days, subjects refrained from alcohol, caffeine, and (intensive) 
physical exercise for at least 24 hours, as these factors are known to potentially influence 
exercise performance. During the 3 measurement days, subjects were tested at the same 
time of day, while measurements were performed in a temperature-controlled testing room 
with the temperature set at 19ºC.  
The incremental maximal arm crank exercise test was preceded with: 1. Repeated, 5-minute 
arterial occlusions of 220 mmHg on the arms (IPC), 2. Repeated, 5-minute arterial occlusions 
of 220 mmHg on the legs (RIPC), or 3. SHAM-intervention, in which the cuffs were repeatedly 
inflated for 5-minute cycles of 20 mmHg on the legs (Figure 1). Given the nature of the 
lesions, SCI subjects noticed no differences between the RIPC and SHAM-condition and were 
naïve about the purpose of these testing trials. Cuff inflation to 20 mmHg does not alter 
blood flow to the leg [182], and therefore represents a valid SHAM-condition.  
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FIGURE 1. Protocol of the study. Interventions were randomised. IPC, ischaemic preconditioning; RIPC, remote ischaemic 
preconditioning.  
 
Measurements 
Body anthropometric data. Body mass was measured in the seated position on a customised 
weighing chair, while height was reported by the subjects in order to calculate body mass 
index (in kg/m2). Resting HR and BP were measured twice in the supine position on the left 
arm, using a manual sphygmomanometer after 5 minutes of rest.   
 
Incremental maximal arm crank exercise test. The incremental maximal arm crank test was 
performed as described in chapter 3. We recorded total exercise duration in seconds and 
total workload in wattage. Oxygen consumption, respiratory quotient (RQ) and HR were 
represented as the mean of the last 30 seconds of each minute. In addition, we recorded the 
exercise time necessary to exceed RQ >1.00. Resting values were averaged over a 2-minute 
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period. The peak values were measured as the mean of the last 30 seconds in which arm 
crank exercise was performed. 
 
Blood lactate and BORG – Blood lactate level was measured with a finger stick (Lactate Pro 
LT-1710, Arkray), before and after the intervention and within 2-3 minutes after completing 
the maximal arm crank exercise test. Immediately after the maximal exercise test, subjects 
were asked to indicate their perceived exertion on a BORG 6-20 scale. 
Blood pressure - Using a manual sphygmomanometer, BP was measured every second 
occlusion during the IPC intervention, prior to exercise.  
 
Interventions 
IPC was performed in the supine position using bilateral arterial occlusion of both arms, 
similarly to de Groot et al. [16]. The automated occlusion cuffs (E20 rapid cuff inflator, 
Hokanson, USA) were positioned proximally around the upper limbs and alternately inflated 
to 220 mmHg for 5 min. This procedure allows for a complete blockade of the arterial inflow 
in the upper limb throughout these 5 minutes. This ischaemic procedure was repeated 4 
times, each separated by 5 min of reperfusion (during which the contra-lateral upper limb 
was occluded). On another day, RIPC was applied using the same protocol as described 
above for the IPC, except that the occlusion cuffs were now placed proximally around the 
lower limbs. On a third occasion, subjects followed a SHAM-intervention, which was 
identical to the RIPC procedure with the occlusion cuffs being inflated to 20 mmHg.  
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Statistics 
Data is presented as mean ± SD, unless stated otherwise. In order to assess whether IPC 
enhances performance in SCI, a Students’ paired t-test was used to calculate the difference 
between the IPC and SHAM-session to answer the first aim of our study. Secondly, to study 
whether a remote effect was present (i.e. the second aim of our study), a Students’ paired t-
test was used in order to compare the RIPC with SHAM-session. Differences were considered 
to be statistically significant at P=0.05.  
 
RESULTS 
Impact of local IPC on exercise performance 
Baseline characteristics are presented in Table 1. We found a significantly longer total 
exercise duration when the incremental arm crank exercise was preceded by IPC compared 
to the SHAM-intervention (P=0.05; Figure 2). Workload tended to be higher after IPC 
compared to SHAM (P=0.06). No significant differences were found in maximal oxygen 
consumption between the exercise tests preceded by IPC or SHAM-intervention. Moreover,  
no differences in RQ, HR, perceived exhaustion and time to RQ >1.00 were measured (Table 
2).  
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FIGURE 2. Change in exercise time (in seconds) during an incremental maximal arm crank exercise test after IPC of the 
upper limbs (A) or RIPC of the lower limbs (B) compared to a control trial in 12 spinal cord injured-individuals. Changes in 
exercise time are provided for all 12 individuals. Paired Students’ t-tests indicate a significant improvement in exercise time 
after IPC (P=0.05), but not after RIPC (P=0.60)  
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Table 1. Baseline characteristics of spinal cord injured (SCI) individuals included in the present study (n=12). Values are presented as mean ± SD. 
Subject 
 
Sex Age 
(years) 
Body 
mass 
(kg) 
BMI 
(kg/m2) 
MAP 
(mmHg) 
Level of 
lesion 
(years) 
Time since injury 
(years) 
Sport 
(h/wk) 
Medication 
1 male 51 97 28 91 T10 11  5 - 
2 male 38 58 19 80 T11 10  1 microlax 
3 male 31 72 22 97 T4 13  2 - 
4* male 28 78 23 82 T5 8  1 melatonin 
5 male 45 78 25 85 T4 16 1 - 
6 male 45 69 21 95 T6- 22 2 microlax 
7# male 25 70 21 82 T11 9 4 - 
8 male 26 92 26 105 T4  7 4 sodium picosulfate 
9 male 23 78 23 93 T12 9 1 movicolon, solifenacin, 
levocetirizine 
10 female 46 62 26 90 T10 43 2 benzodiazepine, lamotrigine, 
clomipramine, promethazine, 
propranolol, fluimucil, 
transipeq 
11 male 57 86 29 93 T8 25 3 - 
12 male 32 72 24 82 T10 15 2 microlax 
Average
ee 
 
11/1 37
±1
1 
76±11 24±3 90±8 n/a 16±10 2±1 n/a 
#Incomplete thoracic sensory lesion, AIS B.*SCI due to surgical removal benign tumour 
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Table 2. Characteristics of the maximal arm crank exercise test in spinal cord injured individuals (n=12) when preceded by SHAM (4X5-min 20 
mmHg on both legs), local IPC (4X5-min arterial occlusion to 220 mmHg on both arms), and remote IPC (4X5-min arterial occlusion to 220 
mmHg on both legs). Values are presented as mean±SD. P-value represents a Student’s paired t-test between SHAM and IPC (i.e. local IPC), or 
between SHAM and RIPC (i.e. remote IPC). 
Parameter SHAM IPC RIPC P-value 
(SHAM vs 
IPC) 
P-value          
(SHAM vs RIPC) 
Exercise time (s) 636±184 662±176 642±182 0.05 0.60 
Maximal load (W) 106±31 110±29 106±30 0.06 0.74 
VO2max (ml/min per 
kg) 
25.2±6.5 25.3±5.7 24.1±5.5 0.94 0.23 
Lactate, mmol/L 8.0±2.8 9.3±2.9 8.9±3.0 0.41 0.26 
BORG-score 18±3 18±3 17±3 0.28 0.43 
Peak heart rate 
(bpm) 
176±19 173±17 178±19 0.08 0.93 
Respiratory quotient 1.14±0.12 1.15±0.12 1.19±0.13 0.73 0.04 
Time to RQ  >1.00 (s) 455±214 440±155 427±164 0.76 0.42 
IPC, ischaemic preconditioning; RIPC, remote ischaemic preconditioning; RQ, respiratory quotient 
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Impact of remote IPC on exercise performance 
No significant differences were found between the RIPC-intervention and the SHAM-
intervention for total exercise time or maximal workload (Table 2). In addition, no 
differences were found for maximal oxygen consumption, HR, time to RQ >1.00 and 
perceived exhaustion among the two tests, while the RQ was significant higher after the arm 
crank exercise test preceded by RIPC compared to SHAM ((P= 0.04) Table 2).  
 
 
DISCUSSION 
In this study the local and remote effect of IPC on arm crank exercise performance in a group 
of SCI individuals was examined. The following findings are presented. First, this study 
demonstrated that IPC applied to the upper limbs (i.e. IPC) in a group of SCI individuals with 
a motor complete thoracic spinal cord lesion can significantly improve exercise performance 
during an incremental maximal arm crank exercise test. This effect of IPC on exercise 
performance was not accompanied by an increase in maximal oxygen consumption. 
Secondly, no impact of IPC was found when the cuffs were applied to the lower limbs (i.e. 
RIPC) preceding an arm crank exercise bout. This study suggests that local IPC successfully 
improves exercise performance in SCI individuals (in line with previous work in able-bodied 
healthy volunteers, including in chapter 6), whereas RIPC does not.   
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This study revealed that a single session of IPC (4 repeated arterial occlusions of the upper 
arm) that precedes a maximal arm crank exercise test improves upper body exercise 
performance in SCI individuals. The average improvement in maximal performance of 4% is 
in line with previous studies that reported improvement in cycle, running and/or swimming 
performance of 1-4% after application of IPC [16, 18, 101, 154]. However, the present study 
design importantly differs from these previous studies. A first important difference is that, in 
contrast to previous studies that included predominantly lower limb exercise (e.g. cycling, 
running, rowing), an arm crank exercise protocol was adopted. Therefore, the study suggests 
that the impact of IPC on exercise performance is not simply related to (lower limb) large 
muscle exercise and/or application of IPC to the lower limbs. A second important difference 
with previous studies is that subjects with a SCI rather than healthy, able-bodied subjects 
were included. Presence of SCI commonly leads to a relatively physical inactive lifestyle 
which has unfavourable consequences for general health and physical fitness [183, 184]. The 
significant improvement in maximal workload suggests that the impact of IPC on exercise 
performance is not restricted to the able-bodied population only.   
 
In contrast with one previous study in able-bodied subjects [153], no improvement in 
exercise performance after RIPC (i.e. IPC applied to the lower limbs) in SCI individuals was 
found. Cardioprotective effects of IPC are, at least partly, mediated through neural pathways 
[178]. Interruption of neural pathways from the lower limbs, as in SCI individuals with a 
complete lesion, may explain the absence of an effect of RIPC on arm crank exercise 
performance in our study. Alternatively, the amount of muscle mass occluded during RIPC 
may also contribute to our observations. Loukogeorgakis et al. [113] demonstrated that 2 
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cycles of RIPC on the contralateral arm did not protect the injured arm after IR-injury, while 
2 cycles of RIPC applied to both legs (i.e. a significantly larger muscle mass) was sufficient to 
protect the arm against ischaemia-reperfusion injury. Participants with a chronic (complete) 
thoracic lesion demonstrate severe muscle atrophy of the lower limbs [185]. Consequently, 
our RIPC stimulus affects a relatively small muscle mass, possibly leading to a too small 
‘dose’ to initiate beneficial effects of IPC. Therefore, possible explanations for the 
observation of a lack of RIPC in SCI individuals relates to the interruption of neural signalling 
and/or the volume of muscle mass available for the RIPC stimulus. 
 
When explaining the absence of an effect of RIPC in SCI above, an important assumption is 
made that RIPC improves exercise performance in the able-bodied population. Despite some 
initial findings that support this assumption [101, 153], it should be emphasised that these 
previous studies were not directly set-up to compare IPC and RIPC and involved a single 
intervention-arm only (i.e. IPC on non-active area). Moreover, one of these studies explored 
“RIPC” by applying IPC to the arms, followed by a swim time trial [101]. Since both arms and 
legs are used during swimming, it is unlikely that a true remote IPC stimulus was applied. 
Therefore, we believe it is highly speculative whether RIPC improves exercise performance in 
the able-bodied population. Hence, at this stage, we can only speculate whether the lack of 
an effect of RIPC on exercise performance in our study is a general finding, or specifically 
relates to the population of SCI individuals. 
 
The present observations raise questions about the potential underlying mechanisms. In line 
with most [18, 102, 156], but not all [16], previous studies, no differences were found for 
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maximum oxygen uptake after application of IPC. Therefore, it is unlikely that a larger 
maximal oxygen uptake explains the larger maximum performance in our study. 
Furthermore, no differences for other parameters that were examined during the 
incremental arm crank exercise test were found, like maximum RQ, time to RQ >1.00 and 
maximum HR. In a previous study, it was established that IPC impairs lactate accumulation 
during submaximal exercise, without affecting oxygen consumption [18]. Changes in 
metabolism may therefore contribute to these findings. To support this hypothesis, 
Schneider et al. have shown that paraplegic subjects have a delayed anaerobic threshold, 
accompanied by an increased rate of lipid utilization, in their upper body musculature 
compared to able-bodied subjects [186]. Furthermore, it has been shown that IPC is 
associated with muscle energy preservation [57, 187]. More specifically, these studies found 
that IPC maintained a higher muscle content of ATP and energy charge potential, and 
decreased muscle lactate content during ischaemia. In a follow-up study [188], the authors 
showed that opening of the mitochondrial ATP-sensitive potassium channels is likely 
contributing to the ATP-sparing effect induced by IPC.  Furthermore, a study by Andreas et 
al. have shown that IPC positively influences muscle metabolism during reperfusion as 
evidenced by an increased production of phosphocreatine (Pcr) [189]. However, as we did 
not find any differences in maximal oxygen consumption and were not able to measure 
some of the suggested local mechanisms, we can only speculate about the potential causes 
for the observed performance enhancement in SCI after IPC. 
 
Clinical Relevance. As sport participation in SCI has become increasingly popular on 
competitive level [175], SCI individuals have tried to enhance their exercise performance 
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with varying stimuli, including boosting [176]. ‘Boosting’ is defined as the intentional 
induction of autonomic dysreflexia and while boosting can lead to a significant increase in 
improvement in race time, it can be detrimental for health and is therefore forbidden [176]. 
IPC importantly differs from ‘boosting’ as IPC relates to a physiological stimulus (rather than 
pathological stimulus). In addition, we measured HR and BP during all three different 
interventions (unpublished data) to control for a ‘boosting‘ like stimulus. In this study, no 
differences between the interventions or during the interventions were found, that would 
be present during a ‘boosting’ like stimulus. Therefore, IPC is likely to serve as a legal, non-
harmful stimulus to enhance physical performance.   
 
Limitations. A potential limitation of our study is that we did not include an able-bodied 
control group. Although performance enhancement IPC in able-bodied individuals is already 
well studied and our results are in line with these studies, based on our results, we cannot 
make conclusions about whether RIPC is possible in relation to exercise enhancement due to 
the lack of a control group. A second limitation is that upper body muscle tissue in able-
bodied persons differs from SCI. Indeed, adaptations include an increase in the oxidative 
capacity of the upper-body musculature with a reduction in glycocogenolysis and a higher 
rate of lipid utilization [186]. Finally, we adopted a maximal incremental test, which 
represents a reliable test. However, it does not reflect a “real world” situation for the athlete 
during a sporting event. Consequently, our results cannot be simply extrapolated to a sport 
performance benefit for the individual athlete. 
In conclusion, it was found that local IPC (applied to the upper limbs) significantly improved 
arm crank exercise performance during an incremental exercise test in subjects with a 
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complete thoracic SCI. This beneficial effect of IPC on exercise performance cannot be 
explained through changes in (sub)maximal oxygen uptake. Furthermore, and in marked 
contrast to IPC, no effect of RIPC (applied to the lower limbs) on arm crank exercise 
performance in SCI individuals was found. Whether these latter results also apply to healthy 
individuals should be subject of future research. 
In chapters 4 and 5, it was established that IPC is effective in protecting the endothelium 
against IR-injury in healthy, young individuals. Our observations from chapter 6 and 7 
provide further evidence for a strong link between IPC can exercise (performance). 
Interestingly, both IPC and exercise share the stimulus of repeated exposure to (local) 
ischaemia and reperfusion. To further focus on this link, it is also suggested that exercise 
exert similar preconditioning effects as IPC, with the consequence that (acute) exercise can 
precondition tissue and prevent or attenuate the impact of IR-injury. Therefore, in the next 
study, it is investigated whether exercise has similar preconditioning effects as IPC.  
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INTRODUCTION 
Despite significant improvement in (pharmacological) treatment in recent decades, 
cardiovascular diseases remain the world’s leading cause of death. As described in detail in 
previous chapters, IPC has been suggested as an effective strategy to reduce the negative 
consequences of IR-injury. Moreover, it is hypothesised that IR-injury of the endothelium 
contributes to cardioprotection and, subsequently, contributes to the outcomes in patients 
with coronary heart disease [190]. 
Exercise may also have preconditioning effects that reduces endothelial IR-injury, especially 
since some types of exercise have similar characteristics as IPC (i.e. short, repeated bouts of 
exercise/ischaemia). Preliminary data from animal studies revealed that (acute) exercise 
reduces cardiovascular injury associated with prolonged (potentially lethal) ischaemia [191-
193].  Recently, Michelsen and co-workers provided further support that exercise may 
possess preconditioning effects [17]. They found that interval running exercise (4x2-min) and 
IPC (4x5-min) in humans, followed by blood withdrawal and perfused through isolated rabbit 
hearts, were similarly effective in reducing infarct size in the rabbit hearts [17]. These effects 
of exercise on cardiac IR-injury may also be present in humans adopting an in vivo model of 
endothelial IR-injury. 
To date, little is known about the possible preconditioning effects of (acute) exercise in 
humans. Therefore, the aim of this study was to investigate the ability of an acute bout of 
exercise to prevent endothelial IR-injury in healthy, young humans. To study endothelial IR-
injury, we adopted a frequently used and validated human in vivo model, similar to chapter 
4 and chapter 5. Secondly, it was hypothesised that a single bout of interval exercise 
represents a more potent preconditioning stimulus than endurance exercise, as interval 
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exercise would lead to short periods of local deoxygenation of the working muscle mass, 
thereby mimicking ‘mechanical’ IPC application. Moreover, based on studies in which 
different modalities of exercise were studied [194], interval exercise presumably  leads to 
different shear patterns, which lead to distinct shear patterns working on the endothelial 
layer. Therefore, the second aim was to compare the ability of a single bout of interval 
exercise versus endurance exercise to prevent endothelial IR-injury in healthy, young 
humans.  
 
METHODS 
Subjects 
A total of 17 healthy volunteers were included to participate in this study (Table 1). All 
subjects performed regular physical activity, with an average sport participation of 6.7±5.0 h 
(range 1.5 to 17.5 h). Subjects were non-smokers, free of any cardiovascular disease, 
diabetes mellitus, hypertension (diastolic >90 and/or systolic BP >140 mmHg) and 
hypercholesterolemia (total cholesterol >6.5 mmol/L). In addition, obese subjects (BMI ≥30 
kg/m2) and those on medication potentially influencing the cardiovascular system were 
excluded. The study was conducted according to the Declaration of Helsinki (2000) and 
approved by the Ethics Committee of the Radboud University Nijmegen Medical Centre.  
  
  
110 
 
Table 1. Baseline characteristics (n = 17) 
Subject characteristics Subjects 
Male/female 10/7 
Age, yr 23 ± 4 
Body mass index, kg/m2 21.8 ± 1.5 
SBP, mmHg 121 ± 9 
DBP, mmHg 73 ± 8 
Heart rate, bpm 57 ± 9 
Cholesterol, mmol/l 4.3 ± 0.5 
Glucose, mmol/l 3.6 ± 0.5 
 
Maximal Incremental cycling test 
Maximum oxygen uptake, ml/kg/min 
 
 
52.4 ± 8.8 
Maximum heart rate, bpm 193 ± 11 
Maximum workload, wattage 309 ± 74 
Post-exercise blood lactate, mmol/l 13.0 ± 1.6 
Maximum respiratory exchange ratio 1.20 ± 0.06 
Values are presented as mean ± SD. SBP, systolic blood pressure; DBP, diastolic blood 
pressure.  
 
 
Experimental design 
First, subjects performed an incremental cycling test to determine maximum oxygen 
consumption (VO2max) and maximum workload (wattage). Subsequently, participants 
visited our laboratory on 3 different occasions (separated by at least 7 days, with a 
maximum of 1 month, Figure 1). During these visits, brachial artery endothelial function 
(using FMD) was examined under resting conditions, after the intervention (i. interval 
exercise, ii. endurance exercise and iii. control), and after IR (20-minutes of arm ischaemia, 
20-minutes of reperfusion). In this study, 20 minutes reperfusion was chosen. This 
represents a small adjustment compared to the protocol adopted in chapter 4, since it was 
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found that 15 minutes of reperfusion was not sufficient for vessel diameter to return to 
baseline values. To examine local tissue oxygenation in the physically active lower limbs 
during the exercise bouts, near infrared spectrometry (NIRS) was placed on the thigh during 
exercise. All measurements for a subject were performed at the same time of day, whilst the 
order of testing (interval exercise, endurance exercise, and control) was randomised 
between subjects. The randomization procedure was performed using the Statistical Package 
for the Social Sciences (SPSS, version 20). 
 
Day 1: Incremental cycling test 
Subjects completed an incremental exercise test on a stationary bike as described in chapter 
3. All tests included in our study met at least 3 out of 4 most often used quality assessment 
points: ±10 beats/min of the predicted maximum HR (208-age*0.7), levelling off VO2 (<150 
mlO2 during last minute), post-exercise RER >1.1, and post-exercise lactate of >8.0 mmol/L 
[122].  
Day 2-3-4: Experimental protocol 
Subjects were instructed to abstain from caffeine, chocolate, alcohol and high doses of 
vitamin C for at least 18 hours before testing and were instructed to not perform strenuous 
exercise 24 hours before testing. Before each experiment, subjects refrained from food 
ingestion for at least 4 hours and were instructed to have a standardised meal on the 
measurement days (sandwiches with jam without butter). All subjects were tested at the 
same time of day to prevent diurnal variation in FMD response, while the measurements 
were performed in a temperature-controlled testing rooms and using recent guidelines of 
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FMD [34] and as described in chapter 3. Women were consistently tested in the luteal phase 
of their menstrual cycle [195]. 
The experimental protocol started with a 15-minute rest period in the supine position, 
followed by assessment of BP using a manual sphygmanometer (Welch Allyn pressostabil, 
The Netherlands) at the left upper arm. Subsequently, brachial artery endothelial function 
was examined using the FMD on the right arm. This was followed by a 43-minute 
intervention that consisted of: i. interval exercise, ii. endurance exercise, or iii. control period 
of rest in the supine position. Both exercise bouts were isocaloric and workload was 
individually calculated based on the maximum incremental test on day 1. This means that 
the total work performed by the individuals was the same between the endurance and 
interval exercise bout, excluding the possibility that differences in caloric expenditure could 
affect our outcomes. During exercise, we continuously monitored HR and local oxygenation 
of the right thigh using NIRS. Blood lactate concentration was measured immediately before 
and after the exercise bouts. Ratings of perceived exertion were obtained at the end of the 
exercise intervention, just before the cool-down period using a BORG 6-20 scale. After 
exercise, subjects rested for 30 minutes in the supine position in which another FMD was 
performed at the end of this period. Then 20 minutes of upper limb ischaemia and 20 
minutes of reperfusion were applied, where after brachial artery FMD was measured again in 
order to determine the impact of IR-injury on the right arm.  
Ischaemia-reperfusion injury 
A rapid inflation/deflation pneumatic cuff (E10 rapid cuff inflator, Hokanson, USA) was 
positioned proximally around the right upper arm. IR was induced by 20 minutes of occlusion 
(cuff inflation to 220 mmHg) of the brachial artery, followed by 20 minutes of reperfusion. 
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This method represents a method to assess endothelial changes to IR and was already used 
in chapter 4 and chapter 5. As the vascular diameter did not return to baseline values after 
15 minutes of reperfusion in the study conducted in older subjects (chapter 4), a 20 minutes 
reperfusion period was adopted to ensure diameter to return to baseline. Assessment of 
prolonged ischaemia (40-60 minutes), as applied in animal studies to the myocardium, is for 
obvious reasons not possible in humans 
 
Interventions 
Interval exercise 
After a 10-minutes warm-up period at 30% of maximum workload, subjects performed ten 
1-minute cycle exercise bouts at 100% of maximum workload. These 100%-bouts were 
separated by 2-minute recovery periods at with cycle exercise at 25% of maximum workload. 
The interval exercise session was finished with a 5-minute cool-down period at 30% of 
maximum workload. 
Endurance exercise.  
Cycle endurance exercise consisted of a 10-minute warm-up period at 30% of maximum 
workload, followed by a 28-minute exercise at 50% of maximum workload. The cycle 
endurance exercise session concluded with a 5-minute cool-down period at 30% of 
maximum workload. We ensured that subjects performed the same amount of total 
workload during both exercise bouts. 
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Control  
Subjects rested in supine position for 43 minutes. 
  
 
Figure 1. Experimental design (FMD: flow-mediated dilation). 
 
Measurements 
Flow-mediated dilation 
All measurements were performed in a temperature-controlled room (22.5°C) and using 
recent guidelines of FMD [34], as described in more detail in chapter 3.    
 
Near-infrared spectroscopy 
NIRS was used to measure local oxygenation in the lower limb tissue during exercise by 
assessing regional concentration changes in oxyhaemoglobin (O2Hb) and deoxyhaemoglobin 
(HHb) using a continuous-wave near-infrared spectrophotometer (OXYMON, Artinis Medical 
Systems, the Netherlands). The NIRS optodes were positioned on the right thigh, twelve 
centimetre proximal to the fibular head, on the vastus lateralis muscle parallel to the long 
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axis of the muscle. NIRS measurements were performed continuously. The changes in 
absorption measured by NIRS are converted into estimates of concentration changes of 
O2Hb and HHb. The sum of O2Hb and HHb reflects changes in blood volume, represented by 
the total haemoglobin signal (tHb) (Figure 2).  
 
Figure 2. Near-infrared spectroscopy data for 1 subject. Upper graph (A) indicates interval exercise and bottom graph (B) 
indicates endurance exercise. Green line, total haemoglobin(tHb); Blue line, deoxyhaemoglobin(HHb); Red line, 
oxyhaemoglobin(O2Hb); X-axis, time(s); Y-axis, Hb-concentration(µMol); Vertical lines represent markers given every 3 
minutes for additional data-analysis afterwards. 
 
Near-infrared spectroscopy analysis 
Baseline O2Hb level was determined by averaging the 7-minute baseline period during 
warm-up. This typically represented a stable recording of O2Hb (Figure 2). Subsequently, for 
each intervention total O2Hb area-under-the-curve (HbO2 total area) was calculated. 
Secondly, local oxygenation status was determined by calculating the positive area-under-
the-curve above baseline (‘positive area’) and local deoxygenation/hypoxia as the negative 
area-under-the-curve below baseline (‘negative area’). 
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Statistical analysis 
All statistical analyses were performed using SPSS 20 (SPSS, Chicago, IL, USA) software. Data 
were reported as mean±SD unless stated otherwise. Statistical significance was set at 
P<0.05. Baseline characteristics were compared with a paired Student’s t-tests. To evaluate 
the effect of (different types of) exercise on endothelial IR-injury, we used a linear mixed 
model (LMM) with random factor ‘subject’ and fixed factors ‘intervention’ (interval exercise, 
endurance exercise, or control), ‘time’ (pre-intervention, post-intervention and post-IR) and 
the interaction ‘intervention*time’. This differs from the analyses that were used in chapter 
4 and chapter 5 where we adopted a 3-way ANOVA. The LMM represents a more advanced 
method that allows for controlling for various factors using this study design. This strategy 
was not available to us when performing the previous studies. In an additional analysis, 
shear rate area-under-the-curve and baseline diameter were added as covariates. and the 
analysis for FMD were repeated using allometric modelling [119], for reasons described in 
chapter 3.  
 
 
Results 
Interval exercise resulted in a higher post-exercise blood lactate, average HR and post-
exercise BORG-score compared to endurance exercise (Table 2). There were no significant 
differences in (pre and post-exercise) BP between both exercise bouts (Table 2). During the 
endurance exercise bout, HR and estimated VO2-uptake were 152±19 bpm and 33.9±10.6 
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mLO2/kg/min (i.e. 64±14% of VO2peak). During high-intensity exercise, HR and estimated VO2 
uptake of the first bout of high-intensity exercise was 167±11 bpm and 38.8±9.7 
mLO2/kg/min (i.e. 73±11% of VO2peak). The last bout of high-intensity exercise was performed 
at 188±11 bpm and 49.4±9.7 mLO2/kg/min (i.e. 95±6% of VO2peak). HR and estimated VO2 
uptake during the rest intervals, was 147±14 bpm and 30.0±8.7 mLO2/kg/min (i.e. 58±13% of 
VO2peak). 
 
Table 2. Exercise characteristics 
Parameter Endurance exercise P-value Interval exercise P-value  
 Pre Post Pre Post  
SBP, mmHg 114 ± 10 109 ± 11 0.020 113 ± 9 108 ± 8 0.008 
DBP, mmHg 70 ± 11 70 ± 10 0.887 68 ± 7 69 ± 7 0.771 
Lactate, mmol/L 2.4 ± 0.8 3.3 ± 2.2 0.141 2.7±1.2 14.0 ± 2.7* 0.000 
BORG-score  15 ± 2   18 ± 2*  
Peak heart rate  160±18   188±11*  
Values are presented as mean±SD. P-value represents a Student’s paired t-test between pre 
and post-exercise. *Significantly different between endurance and interval exercise at 
P<0.05 (Student’s paired t-test). SBP, systolic blood pressure; DBP, diastolic blood pressure. 
 
Impact of exercise on endothelial IR 
A significant interaction effect for the change in brachial artery FMD% after IR was found 
(P<0.001, Table 3). Whilst post-hoc analysis revealed no change in brachial artery FMD 
immediately after the intervention for all 3 conditions, a significant decrease was observed 
in FMD after IR during the endurance and control condition (LMM ‘time’, P<0.001).  In 
marked contrast, the decline in FMD after IR was prevented by interval exercise (Post-hoc 
P=0.56, Figure 3). Repeating this analysis using allometric scaling to control for the potential 
impact of (inter- and intra-individual differences in) baseline diameter confirmed the 
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presence of a significant intervention (P=0.034), time (P<0.001) and intervention*time-effect 
(P<0.001). 
 
The IR-procedure did not change brachial artery diameter (Table 3). No change in diameter 
was found after the control and endurance exercise session, whilst a significant increase in 
diameter was observed immediately after interval exercise (P<0.05, Table 3). The eliciting 
shear rate stimulus SRAUC was significantly higher after interval exercise (Table 3), but 
returned to baseline levels during the post-IR measurement. The control and endurance 
exercise intervention showed no changes in SRAUC. To statistically control for the potential 
influence of these parameters, the  analyses were repeated with the linear mixed model 
analysis with baseline diameter and SRAUC as covariates. The analysis confirmed our earlier 
findings, and revealed a significant interaction-effect between time and intervention 
(P<0.001), with a decline in FMD after IR for the control and endurance exercise sessions, 
but not when interval exercise preceded IR. 
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Figure 3. Flow mediated dilation ((FMD) % from baseline) at baseline, post-intervention and post ischaemia-reperfusion (IR) 
in control-, endurance- and interval intervention (n=17). Error bars represent standard error of the mean. *P<0.05. 
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Table 3. Brachial artery characteristics pre, post-intervention and post-IR in the control-, endurance- and interval intervention (n=17). 
 
  ‘time’ LMM 
  Pre Post-
Control 
Post-IR ‘time’ ‘intervention’ Time*intervention 
Baseline diameter, mm Control 3.65±0.55 3.62±0.54 3.75±0.64 0.20 0.29 0.11 
 Endurance 3.59±0.64 3.61±0.66 3.69±0.65    
 Interval 
 
3.62±0.68 3.81±0.69 3.67±0.62    
FMD, mm Control 0.26±0.08 0.25±0.11 0.16±0.09* <0.001 0.021 <0.001 
 Endurance 0.27±0.10 0.30±0.09 0.14±0.06*    
 Interval 
 
0.27±0.11 0.25±0.11 0.25±0.09    
FMD, % Control 7.1±2.3 6.9±3.0 4.3±2.3* <0.001 0.036 <0.001 
 Endurance 7.8±3.1 8.5±2.8 3.8±1.7*    
 Interval 
 
7.7±3.1 7.0±3.4 7.2±3.1    
SRAUC, s (103) Control 29.9±6.9 28.1±10.3 26.5±11.7 0.004 0.001 0.32 
 Endurance 31.8±7.1 33.8±6.9 28.0±8.1    
 Interval 
 
32.5±9.8 38.0±7.1* 30.6±8.5    
Time to peak diameter, s Control 49±15 53±21 46±25 0.001 0.25 0.37 
 Endurance 48±19 60±20* 43±15    
 Interval 47±20 65±23* 53±25    
Values are presented as mean ± SD. IR, ischaemia-reperfusion; FMD, flow-mediated dilation; SRAUC, area under the shear rate curve. *Post-hoc 
significantly different from Pre at P < 0.05. 
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Impact of exercise on local oxygenation status 
NIRS data showed no significant differences between the endurance and interval exercise 
bout for the total area-under-the-curve for HbO2 (63311±18048 and 60008±27941 A.U., 
respectively, P=0.21) and the area below baseline (-1.24±1.33 and -1.72±0.96 A.U, 
respectively, P=0.13). Endurance exercise was associated with a significantly smaller area 
above baseline compared to the interval exercise bout (1.28±1.67 and 3.72±2.38 A.U, 
respectively, P=0.03). Nonetheless, clear differences in the pattern of local HbO2 can be 
observed between the endurance and interval exercise bout (Figure 2). 
 
 
DISCUSSION 
To the best of our knowledge, this is the first study examining whether an acute bout of 
exercise is able to protect the vascular endothelium against IR-injury in humans in vivo, and 
whether such preconditioning effect of exercise depends on the modality of exercise. The 
major finding of this study is that a single bout of interval exercise is able to protect the 
brachial artery endothelium against IR-injury in vivo in healthy young subjects. The 
observation that lower limb exercise (i.e. cycling) induced protective effects in the upper 
limb (i.e. brachial artery), suggests the presence of a remote preconditioning effect of 
interval exercise. Interestingly, when IR was preceded by a single bout of moderate-intensity 
endurance exercise, post-IR brachial artery endothelial function was impaired to a similar 
extent compared to the control condition. These findings indicate that a single, short-
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duration bout of interval exercise, but not endurance exercise, possesses remote 
preconditioning effects in healthy, young subjects.  
 
In this study, IR resulted in a significant decrease of ~40% in brachial artery endothelial 
function, measured as FMD. This reduction of 40% during the control condition is in line with 
chapter 4 and chapter 5, as well as those from others who adopted a similar protocol (38-
65%) [107, 109, 113, 114].  A decrease in brachial artery FMD after IR was observed, which 
may reflect changes in tissue damage after ischaemia reperfusion. Furthermore, these 
results indicate that interval exercise is able to prevent endothelial IR-injury, which suggests 
that interval exercise induces preconditioning effects. An interesting observation is that 
exercise was performed using the lower limbs, whilst protection against endothelial IR was 
observed in the upper limbs. This observation provides support for a remote preconditioning 
effect of interval exercise, which suggests that also other vascular beds are protected against 
IR-injury.  
 
In contrast to the observations during interval exercise, we found that the reduction in FMD 
after endothelial IR-injury remains present after performance of a bout of moderate-
intensity endurance exercise in healthy subjects. Since the total workload was similar 
between both exercise bouts, the distinct impact on endothelial IR-injury may relate to 
differences in tissue oxygenation. Although not directly measured, another explanation 
could relate to differences in flow pattern, leading to  potentially more shear stress during 
interval exercise.  More specifically, it was hypothesised that interval exercise in contrast to 
endurance exercise would reveal similarities with ‘mechanical’ IPC, as both interval exercise 
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and IPC induce repeated, short periods of tissue de-oxygenation. Whilst our NIRS data 
revealed no differences in total deoxygenation between interval and endurance exercise, we 
indeed demonstrated that interval exercise, but not endurance exercise, induced repeated, 
short periods of ischaemia (Figure 2). This suggests that the pattern, rather than the total 
amount, of oxygenation contributes to the protective effects of a single bout of exercise on 
endothelial IR-injury. Future studies are warranted to better understand these potential 
underlying protective mechanisms of exercise on endothelial IR. 
 
A recent paper studying the effects of exercise preconditioning, found that preconditioning 
effects of exercise are mediated by a blood born factor [17]. Moreover, they found that the 
preconditioning effects of a single bout of (interval) exercise are, at least partly, mediated 
through opioid receptors [17]. Exercise induces release of β-endorphins, especially when 
performed at higher intensity levels that lead to significant elevations of blood lactate [196-
198]. Since β-endorphins contribute to the cardioprotective effects of IPC through their 
effects on opiod receptors, distinct release of β-endorphins between endurance and interval 
exercise (such as evident for blood lactate levels, Table 2) may contribute to these findings. 
Future studies are warranted to explore the potential role of β-endorphins and opioid-
receptors in the preconditioning effects of exercise. 
 
Another explanation for the preconditioning effects of interval exercise may relate to the 
NO-pathway. Although endurance exercise training improves eNOS expression [199], some 
recent evidence suggests a superior upregulation of the NO-pathway after interval training 
[200]. Another explanation may relate to the rapid depletion of ATP during interval exercise 
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compared to endurance exercise. Depletion of ATP activates the ATP-dependent potassium 
(K-ATP) channels in order to maintain the resting potential of the cells and to prevent cell 
death [201, 202]. The mitochondrial K-ATP channels are activated via a molecular cascade in 
which adenosine stimulates a G-coupled receptor protein transmitting the signal to a protein 
kinase C and, more importantly, are suggested to play a significant role in IPC [5, 202]. 
Whether (interval) exercise has protective preconditioning effects through eNOS and/or K-
ATP channels remains unclear and should be subject of future research. 
 
Study limitations 
A limitation of our study is that there were no measures included to explore the potential 
mechanisms involved underlying the protective effects of (high-intensity interval) exercise 
on endothelial IR. However, the study was designed to explore whether (different forms of) 
excise could prevent endothelial IR-injury. Another limitation is that only healthy young 
individuals were included, and did not assess exercise bouts of different duration and/or 
intensity. Ischaemic events typically occur in an elderly population with cardiovascular risk 
and/or diseases. Whether exercise has similar preconditioning effects in groups with 
cardiovascular disease or risk is currently unknown and should be subject for future 
research. In this light, it is important to realize that the previous chapters showed that 
‘traditional’ IPC in older subjects (chapter 4) and heart failure patients (chapter 5) fails to 
protect against the negative consequences  of IR-injury. Exercise may represent a suitable, 
effective and safe alternative as a preconditioning stimulus in these groups. Furthermore, 
previous work has highlighted the impact of duration and intensity of exercise on the 
vasculature. Therefore, we cannot exclude the possibility that endurance exercise of 
  
125 
different intensity (i.e. above lactate threshold) or duration has preconditioning effects. 
Finally, we used the brachial artery endothelial function as a model to study IR-injury in the 
forearm. Although this model is frequently used by others as stated before, caution should 
be taken when extrapolating our findings to other vascular beds, such as the coronary 
circulation. Future studies are recommended to further validate this technique. 
 
Clinical relevance 
Exercise training has strong cardioprotective effects. Approximately 40% of the beneficial 
effects of exercise training can be explained by improvement in cardiovascular risk factors 
[31]. Possibly, the preconditioning effects of a single bout of (interval) exercise may 
contribute to the cardioprotective effects of exercise. Moreover, repeatedly performing this 
type of exercise (and therefore preconditioning) may protect against ischaemia-reperfusion 
injury. Previous work found that habitual endurance [47] or resistance [97] exercise (partly) 
prevented endothelial ischaemia-reperfusion injury. A potential implication of our results is 
that exercise training may possess preconditioning effects that ultimately protect against 
ischaemia-reperfusion injury. Future studies are needed to explore this hypothesis.  
 
Conclusions 
This study showed the ability of interval exercise to prevent endothelial IR-injury in a group 
of healthy young subjects, whilst this effect of exercise was absent when IR-injury was 
preceded by a single bout of short-duration, moderate-intensity endurance exercise. These 
protective effects of lower limb interval exercise were observed in the upper limb arteries, 
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which suggests that the preconditioning effects represent a ’remote’, rather than a local, 
effect of interval exercise. These findings may have potential clinical relevance for the 
protection of the heart and other tissues against IR-injury by (interval) exercise.  
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9 
Synthesis 
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Ischaemic preconditioning, a brief historical overview 
Almost 30 years ago, Murry and co-workers [4] described the protective effect of IPC after a 
prolonged period of oxygen deprivation in the heart of dogs [4]. Their landmark study 
demonstrated that IPC prior to IR-injury resulted in a marked reduction in cardiac cellular 
damage of about 75%. Shortly after, others found that IPC also induced protective effects in 
other organs, such as the kidney  [203] and the liver [204],which was confirmed by others 
who used different animal species and diverse organs sites [5]. In 1993 Przyklenk and her 
group described for the first time that IPC was also effective in areas that were not directly 
related to the IPC-intervention site [6]. This phenomenon is commonly referred to as RIPC 
and is of particular importance as it has marked advances when translating IPC to clinical 
care [112, 205]  
 
IPC and the difficulties into translating the results into the clinic 
In early research, primarily young, healthy animals were used to explore the benefits of IPC 
to improve understanding of the effects and mechanism of IPC. Although this work was very 
important, questions arose whether these models reflected the average cardiovascular 
patient and, subsequently, research was performed in diseased animals or in animals 
possessing certain cardiovascular risk factors [206]. Szilvassy et al. [207] reported for the first 
time that hypercholesterolemia, a well-known risk factor for developing cardiovascular 
disease, negatively influenced the responses to IPC [207]. It was established that 
hypercholesterolemia blocked the preconditioning effects in a rabbit model, which was 
irrespective of the development stage of atherosclerosis. This study was of major 
importance, as it provided the first evidence that cardiovascular disease/risk may negatively 
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affect efficacy of IPC (in animal models). In 1998 the same group published a review in which 
it was questioned whether IPC was a “healthy heart phenomenon” [208]. In this review, the 
complicated relation between disease state and preconditioning was discussed. 
Furthermore, it was concluded that clinically relevant pathological models were needed to 
assess the typical consequences of a clinically relevant disease state on efficacy of IPC. 
Unfortunately, to date, still a relatively small sample of research in the field of IPC is 
dedicated to gain insight into the impact of cardiovascular disease/risk on efficacy of IPC 
[209].  
Diabetes is known to be a major risk factor for the development of cardiovascular disease 
[210]. Hence, a substantial number of patients with cardiovascular disease, and therefore 
potentially eligible for IPC-based interventions, are diagnosed with type 2 diabetes. 
Interestingly, an extended Pubmed research by Przyklenk  [211] showed that diabetes was 
only included in 2 percent of the used models to assess the effect of IPC. Similarly, the 
impact of ageing, i.e. an important risk factor for cardiovascular disease and highly present in 
clinical populations that may benefit from IPC, was included in only 4% of the papers 
published [211]. Consequently, it was demonstrated that the vast majority (>90%) of IPC-
related studies has been conducted using healthy, juvenile or adult populations that do not 
manifest the risk factors and comorbid conditions typically seen in patients with 
cardiovascular disease [212]. Therefore, only a few studies have contributed to the 
translation of IPC into the clinical setting. This is of special importance since the benefits of 
(traditional models and protocols of) IPC may be reduced in patients with cardiovascular 
disease/risk [213]. The lack of well-designed, clinical studies is an important factor for the 
difficulties of implementing IPC in daily practice [212, 213]. 
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Another important limitation of previous work examining the IPC-effect in animals, is that 
animals often display a different pathological response to ischaemia or cardiac damage 
when compared to humans. These species differences further complicate the extrapolation 
of the results to clinical practice [209]. For example, animals respond differently to (the 
duration of) ischaemia, which is a major determinant of (cardiac) damage. Moreover, 
substantial between-species differences have even been reported for the impact of duration 
and location of infarction [214]. Another factor such as collateralization likely contributes to 
differences in response to ischaemia between species [214]. This highlights the need for 
studies in humans to better understand the impact and mechanisms of IPC as no animal 
model reflects the complexity of the human (coronary) circulation. 
In our studies we included both older humans as well as patients with heart failure; two 
clinically relevant groups that are likely to represent populations that could benefit from IPC-
interventions in real life situations. Unfortunately, we were not able to study the effects of 
IR-injury on the myocardium. Instead, we used a surrogate model, which involved 
assessment of vascular function of the brachial artery.  
 
In order to observe the effects of IR-injury in these groups, the FMD of the brachial artery as 
a surrogate marker was used, as is described in chapter 3. Although the consequences of IR-
injury and IPC could be observed, there are some clear limitations about the methods we 
have used. First, although there exists a strong correlation between the functional capacity 
of the coronary arteries and the brachial artery as described before, we still have to be 
careful into translating our results to the coronary arteries. In addition, we were limited to 
the time of ischaemia that could be given to our subjects. However, we were able to detect 
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differences between groups and between the given interventions using this protocol, which 
is similar to others who have used the same protocol[47, 110]. The studies presented in 
chapter 4 and chapter 5 were mainly observational and could benefit from extra analysis, as 
for example neutrophils count after IR-injury, measurements giving more insight into 
possible mechanisms, measurements with acetylcholine to control for endothelial function 
and other non-invasive vascular measurements, as for example Pulsed-wave Doppler.     
Furthermore, and for obvious reasons, we are limited to the time of occlusion of the 
forearm. In our study we used an occlusion period of 20 minutes, which is not as long as the 
typical ischaemic period during a myocardial infarction [215]. Although the ischaemic period 
was relatively short,  it proved to be long enough to find changes in endothelial function 
between healthy subjects and those with CV disease/risk. This model of 20-minutes of 
ischaemia leading to impaired endothelial function (but not necrosis) is clearly different to 
the clinical situation of a prolonged (~60 minutes) ischaemia of the heart, leading to 
impaired endothelial function and necrosis. Although much shorter, this model of 20-
minutes of forearm ischaemia induces reduction in endothelial function. Furthermore, the 
duration of ischaemia may be inferior to the presence of reperfusion. It was for example 
found in cats, that a 90 minutes period of ischaemia alone, did not lead to detectable 
endothelium damage, while a short period of reperfusion after 90  minutes of ischaemia led 
to attenuated endothelial functioning [51]. The negative impact of reperfusion was greater 
after 20 minutes, than after only 2.5 minutes, which is suggestive a pivotal role for (the time 
of) reperfusion in relation to structural and functional damage to the endothelium. Despite 
the obvious dissimilarities with a myocardial infarction, our model is relevant in that it 
induces endothelial damage due to ischaemia-reperfusion injury. This study shows once 
more that the combination of ischaemia and reperfusion causes the detrimental changes in 
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endothelial health and this likely explains why impaired vascular function is present after a 
relatively short period of ischemia.     
As vascular function ultimately returns to normal, our findings are therefore presumably 
based on the consequences of ‘stunning’, which is described as the mechanical dysfunction 
that persists after the restoration of spontaneous circulation [216]. Although stunning does 
reflect mechanical dysfunction, rather than actual tissue damage, in the myocardium 
stunning is the leading cause for early death after successful resuscitation [217] and 
therefore of great clinical importance.  
Taken together, future studies could benefit from better mechanical insight. That way, it 
would be easier to translate the results. In addition, future studies should further explore 
the impact of different protocols, like an increase of the number of cycles or days that IPC 
will be given.  
An important limitation of most clinical studies, is that ischaemia was planned, rather than 
spontaneous (such as present in clinical conditions with a myocardial infarction). Therefore, 
most clinical data relies on studies with elective interventions, as for example coronary 
artery bypass grafting, in which the number of participants studies are typically  low [214]. 
Although there is some evidence that (R)IPC could exert beneficial effects in some type of 
patients, as for example shown in a meta-analysis performed by [218], most studies show 
disappointing results, as pointed out in two major reviews [219, 220]. They found no 
evidence that RIPC reduces mortality associated with ischaemic events, or led to a reduction 
in major adverse cardiovascular events [212]. Furthermore, the study performed by Healy 
and al. stated that data from pilot trials cannot confirm that RIPC has any significant effect 
on clinically relevant end-points, as for example: death, renal failure and stroke [221].  It was 
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discussed that studied populations consisted of heterogeneous groups, which likely affected 
the results. Hence, large clinical trials are needed and it is therefore worth mentioning that, 
recently two huge clinical trials have finished this year [222, 223].  
The study performed by Meybohm et al. [222] represents a large multicentre trial in which 
almost 1,400 patients were analysed. These patients underwent a cardiopulmonary bypass 
and were treated with RIPC or SHAM. No differences in for example death, myocardial 
infarction and other and points were found and the authors concluded therefore that upper-
limb RIPC did not show a relevant benefit among patients undergoing elective cardiac 
surgery. A second large multicentre trial was conducted in over 1,600 patients [223]. 
Patients undergoing coronary-artery bypass graft received either RIPC or SHAM and again no 
differences were found between the groups. These studies again stresses the importance 
about better clinical trials, to understand better how to transfer the preclinical knowledge 
into functioning clinical treatment. Although it must be emphasises that the use of specific 
drugs in these trials may have importantly confounded the negative study outcomes, as 
certain drugs can importantly interfere with the potential benefits of RIPC 
In conclusion, although the effects of IPC are well determined in healthy, young preclinical 
models, translating the evidence into clinical practice is challenging and, at times, 
disappointing [219]. It is clear that the optimal design in IPC-related research does not exist, 
and therefore most evidence should be treated as ‘a pieces of a (very) complicated puzzle’. 
Future studies should focus more on typical clinical populations, and investigate IPC-
interventions preferably in large clinical trials.  Besides, more research should be done in 
specific groups, aiming for a better understanding of an optimized individualized IPC-
protocol, as an increasing body of knowledge, including work presented in chapter 4 and 
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chapter 5, shows that there exists a lot of differences in responsiveness to the application of 
IPC.  
 
Protocols 
Although IPC has been studied extensively, the optimal IPC-protocol is largely unknown and 
represents a topic that is not frequently explored [218, 221]. Therefore most studies use a 
typical design in which an artery is blocked for 3-4 times for 5 minutes, interspersed with 5 
minutes of reperfusion. Multiple variations to this ‘default’ protocol are possible, as one can 
vary in the number of cycles of occlusion, occlusion time, time before IR-injury, pressure of 
the cuff (when the arterial is occluded from outside), location of occlusion cuff, size of the 
ischaemic area, and the frequency of IPC (Figure 1).  Additionally, IPC can be applied both 
locally as well as remotely, whilst studies have revealed that the benefits of (R)IPC are 
present immediately after application, but reappear 24-72 hours post-stimulus [7, 72]. 
Finally, application of repeated, brief periods of vascular occlusion has also been extensively 
studies at the onset of reperfusion (i.e. post-ischaemia rather than pre-ischaemia); a 
phenomenon which is termed ‘ischaemic post-conditioning’ [224]. To make things even 
more difficult, an optimal protocol may vary related to the endpoints being studied [225]. 
Taken together, these various factors make it very difficult to choose an optimal approach. 
Although some work suggests that there is no typical dose-response relationship in IPC, 
some studies tend to show better outcomes with different protocol that provide longer, 
more frequent or larger doses of ischaemia [226, 227]. These suggestions are of special 
importance for the clinical population that may demonstrate a smaller or attenuated efficacy 
of the traditional IPC protocol that consists of 3/4 cycles of ischaemia. 
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Figure 1. Some possible variations to consider, when adopting an IPC-protocol. Figure is inspired by Buchheit et al.[228]   
 
Is IPC trainable? 
Based on the potential impact of IPC, a very interesting question relates to the trainability of 
IPC. A single session of IPC is a safe and easy intervention to apply, but the effect of multiple 
IPC sessions within a certain time frame is currently largely unknown. In 2013, an in vivo 
study in humans was published in which it was demonstrated that daily episodes of IPC 
provided sustained protection from IR-injury [229]. Another recent, in vivo study, performed 
in young, healthy individuals, found improved vascular function after a 7-day daily exposure 
of the arm to IPC (4X5 minutes) [230]. Moreover, improved vascular function was 
established in both the treated arm as well as in the contralateral non-treated arm, 
suggesting that these effects of repeated IPC is trainable and works remotely. The same 
group performed a similar experiment with a longer duration of 8 weeks. Once more, 
improved vascular function was found, while no changes were observed in the control group 
[231]. Although these results in healthy young subjects are promising and provocative, once 
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again the question arises whether patients at increased cardiovascular risk would benefit 
from such a protocol. Interestingly, in a recent published study, the effect of intense RIPC -
training (4X5 minutes brachial artery occlusion, 3 times a day; for a total duration of 20 
consecutive days)  on endothelial function in patients with coronary heart disease was 
studied [232]. In agreement with previous work in healthy volunteers, a significant increase 
in endothelial function was found after continued IPC application. Furthermore, another 
study explored the impact of 300-days of repeated, twice-daily IPC in stroke survivors. 
Remarkably, this study found that repeated IPC resulted in a better rehabilitation post-
stroke, improved cerebral perfusion and significantly fewer stroke-recurrences [233]. This 
suggests that, somewhat in contrast to the application of single IPC in clinical groups, 
repeated IPC may have more potential to improve endothelial function and alter efficacy of 
IPC in subjects with cardiovascular risk/disease.  
 
IPC and performance 
In 2010, de Groot et al. were the first to report the beneficial effects of IPC in relation to 
exercise performance [16]. In their study, young healthy persons performed a maximal test 
after a control session or application of IPC. As hypothesised, they found improved exercise 
performance, as both the maximum oxygen uptake and the total work load improved after 
application of IPC. Inspired by these findings, others conducted similar experiments with 
varying protocols reporting mainly positive effects of IPC regarding exercise improvement as 
reported by Salavdor et al. in their meta-analysis [234]. 
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Protocols 
Studying the true effect of IPC on exercise enhancement is difficult as this intervention may 
introduce a placebo effect which is difficult to control for. Although the goal of most 
investigations is to keep the participants naïve, it remains difficult to implement a proper 
SHAM or a blinded control session as participants will feel the difference between the IPC 
(high pressure cuff, causing some discomfort) and the control of SHAM session (typically cuff 
inflation to low or no pressure). One could argue, therefore, that the effect of IPC could be 
based on a placebo-effect rather than a ‘real’ treatment effect.  
Placebo has proven to be a very powerful in various circumstances. A nice example is 
provided by a study performed by Sihvonen et al. [235]. In this study, patients with 
symptoms of a degenerative medial meniscus tear and no knee osteoarthritis were included 
and randomly assigned to either an arthroscopic partial meniscectomy (normal care) or 
sham surgery. They followed these patients over a period of 12 months and found no 
differences in functional outcome and pain score.  Also in sports it is well known that the 
performing athlete can extend performance limits and/or diminish fatigue perception under 
placebo conditions [236], and it is therefore not surprising that a recent paper boldly stated 
that IPC may not be a real but a placebo-effect [237]. As a counter-argument for a placebo 
effect, Bailey found that IPC altered the lactate kinetics during (sub)maximal running 
exercise, which strongly related to the improvement in 5-km running time (36-s). It seems 
unlikely that a placebo can alter biochemical processes underlying (sub)maximal running 
exercise. Nonetheless, these data highlight the importance that studying the impact of IPC 
on exercise performance should involve a well-designed protocol.  
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When summarizing studies that examined exercise improvement after application of IPC, a 
typical increase of 1-4% in workload, time to fatigue or other ‘performance’ parameters is 
observed. Studies presenting much higher values, as for example the study of Barbosa et al. 
(increase in time to task failure of about 11%), therefore should be interpreted with caution. 
In our study performed in spinal cord individuals (chapter 7), we found a small but significant 
increase in total time to exhaustion during a maximal incremental test on a hand bike. This 
improvement was within the expected range. Importantly, we found similar peak HR levels 
and BORG-scores between the interventions, which suggests that differences in 
performance were not motivational driven. Furthermore, in our 5-km time trial in able-
bodied individuals (chapter 6), we investigated whether local acute IPC was as effective as 
local delayed (24-hours before running) in order to improve exercise performance. In this 
study two remarkable findings were made. First, it appeared that both acute and delayed IPC 
was effective in some, but not in all participants. It was remarkable to observe that 
participants who performed well after application of acute IPC, also performed well after the 
application of delayed IPC. In contrast, individuals who showed poorer results after acute 
IPC, also showed poorer results of delayed IPC. First, these data suggest that inter-individual 
differences exist regarding the impact of IPC on exercise performance, with strong relation 
between the effect of acute and delayed IPC. Secondly, one could argue that a placebo-
effect is less likely, as the change in running time of acute IPC corresponded well with the 
change in running time after delayed (i.e. 24 hours) IPC. 
Exercise related protocols 
In chapter 6, a 5-km time trial was used. The main reasons for choosing the 5-km protocol 
instead of a maximal cycle test, was that a time trial better reflects an athlete performance. 
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In addition, Bailey et al. already successfully conducted a 5 km-trial in relation to IPC [18]. In 
order to minimize variance between 3 familiarisation sessions were performed before the 
actual measurement started, which resulted in a CV of 1.6%. These results are comparable to 
a study conducted by Laursen et al. [123]. In this study, it was investigated whether a time-
to-exhaustion and time-trial exercise would differ in reliability. They found a greater level of 
absolute reliability (less variability) of time-trial compared with time-to-exhaustion running 
tests.  
Although a 5km-trial was the best option in relation the research question of chapter 6, 
there are obviously a few limitations using this protocol. First, subjects can chose different 
pacing strategies, which might have an impact on the time trial. In order to minimize 
difference between the trials, first 3 trials were conducted, prior to testing in order to find 
an optimal strategy. In addition, to correct for this, pacing strategy was measured. Another 
main limitation relates to the fact, that the study presented in chapter 6 was mainly 
observational, although TSI, HR and end lactate were measured. As finish time was the main 
outcome, no gas analysing equipment was used, because this can influence the performance 
during running.  
In contrast to chapter 6, the subjects in chapter 7 were tested using a maximal exercise 
incremental protocol. Like the study in chapter 6, also a time trial in the subjects with a SCI 
was preferred, but as the hand bike did not automatically correct for total workload, a time 
trial was not possible. Therefore a maximal incremental test was chosen, and has the 
advantage that it is well-validated and which has the ability to perform oxygen kinetics 
analysis [238].  
In conclusion, one can state that there exists nog optimal protocol and that IPC testing which 
relates to performance enhancement is difficult, especially as the intervention itself is also 
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hard to control for. The optimal protocol for running would be on an indoor track with 
mobile equipment, but there are only few laboratory’s that are able to conduct these tests 
under these circumstances.  
 
(Proposed) mechanisms 
Several potential mechanisms are discussed in literature. In this section, the most relevant 
mechanisms will be highlighted. A few studies focused on central hemodynamics and 
differences in maximal oxygen consumption. An increase in maximal oxygen consumption 
was found by de Groot and co-workers [16] after application of IPC. However, these results 
were not confirmed by others [18] [152, 155], including our study in spinal cord individuals, 
presented in chapter 7. Possible explanations for these conflicting results relate to 
differences in individuals, protocols and exercise types. In addition, Clevidence et al. 
investigated oxygen uptake during varying intensity levels up to 90% of the maximum 
intensity attained during a maximum test [156]. Again, no differences in oxygen 
consumption were found. Taken together, based on the currently available literature, it 
seems unlikely that a potential effect of ICP to enhance exercise performance is related to 
changes in oxygen uptake kinetics.  
Bailey et al. postulated that IPC-related improvement in blood flow, could lead to a more 
optimal oxygen supply and faster removal of lactate [18]. In addition, it was suggested that 
IPC also improves muscle contraction efficiency, as for example established by Pang et al. 
[57]. These mechanisms may result in lower lactate levels. Indeed, Bailey and co-workers 
found that lactate levels during submaximal exercise showed an attenuated increase across 
incremental levels of submaximal running exercise after the application of IPC. In addition, 
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the same group also demonstrated that IPC prevented vascular impairment measured 
directly after exercise [103]. These findings favour a possible effect in the vasculature and 
may reflect a systemic rather than a local effect, as brachial vascular impairment was 
prevented after IPC application on the legs. In our 5-km study (chapter 6.), we were not able 
to measure lactate levels during exercise, but we measured lactate directly after exercise. 
Interestingly, we found that improvement in finish time was strongly related to a decrease in 
post-exercise blood lactate levels. In some respect, this finding confirms earlier observations 
from Bailey and co-workers, in that IPC may affect lactate metabolism and, subsequently, 
lead to changes in exercise performance. 
In chapter 8, we also explored whether changes in local muscle oxygenation contribute to 
changes in exercise performance after IPC. This hypothesis is based on the fact that IPC-
induced improvement in exercise performance may result from peripheral adaptations 
rather than from central cardiovascular adaptations. In our study, we were not able to 
detect differences in local muscle oxygenation of the quadriceps muscle during running 
exercise. This finding is in contrast with others, who found a marked decrease in local tissue 
oxygenation after the application of IPC [153, 154, 239]. An explanation for these conflicting 
results could relate to the fact that we did not find an overall improvement in exercise 
performance in all subjects. Barbosa et al. did not find a decrease in local oxygen 
consumption at relative intensity, but did find a difference in local oxygen uptake at different 
absolute intensities, most like caused by the longer duration of the IPC treated group [153]. 
Another explanation could relate to the fact that we were unable to measure baseline values 
before the trial, as participants were already performing a warming-up. Therefore, we were 
unable to correct for potential differences at baseline between groups. However, as the 
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previous mentioned studies found an overall lower oxygenation pattern after IPC, it is less 
likely that differences in baseline values explain our findings.  
 
Taken together, IPC-related exercise performance enhancement remains a relatively poorly 
understood phenomenon. Studies so far, suggest favourable effects of IPC in relation to 
(some types of) exercise performance. Based on the heterogeneity of the studies, and the 
relatively short lifespan of this field of research, it is difficult to validly inform athletes about 
the use of IPC. Future research should therefore focus on better understanding of the 
potential underlying mechanisms, better (and more practical) protocols, and exploring the 
optimal conditions and/or protocols to apply IPC.  
 
Exercise preconditioning 
Exercise can serve as interesting therapeutic intervention in order to reduce the 
consequences of  IR-injury. Already in 1978, it was described that chronic swim training in 
rats led to a marked reduction in infarct size after coronary artery occlusion [191]. This 
finding was suggested to be, at least partly, caused by improvement in the vasculature that 
resulted from this 5-week swim training. Possibly, these investigators demonstrated the 
powerful effects of (exercise) preconditioning. First evidence for ‘exercise preconditioning’ 
was provided a decade later, when researchers found the heart to be protected irrespective 
of adaptations within the heart [240].  Since these initial studies , some evidence supports 
the presence of an exercise preconditioning effect on the vasculature [241]. Therefore 
‘Exercise preconditioning’, given the systemic nature and cardioprotective effects, may be 
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driven by a systemic, blood-borne factor. Michelsen and co-workers were the first to explore 
this hypothesis in humans [17]. They found that rabbits’ hearts were protected against IR-
injury when perfused with blood drawn from humans immediately after IPC, whilst a similar 
protection was found when blood was taken after intense, intermittent cycling exercise. 
Interestingly, the same authors demonstrated that these beneficial, protective effects of IPC 
and exercise were abolished when it was co-infused with an opioid receptor-blocker. This 
data, to our knowledge, provides the first evidence in humans that exercise can have 
preconditioning effects that are mediated through a blood-borne factor that works through 
opioid receptors.  
As described in chapter 2, the onset of IPC can be triggered by multiple substances causing a 
signalling cascade that ultimately leads to (cardio)protection. Based on that principle, 
multiple researchers have focused on identifying pharmacological substances that can mimic 
this effect,  without leading to ‘factor X’ that can be used to mimic IPC. Based on the results 
from Michelsen et al. [17], it seems interesting to further explore the role of opioids. A 
recent review explored whether opioids could be prescribed as preconditioning medication 
for myocardial ischaemia [242]. Opioids can function on 4 different type of groups of 
receptors: Mu, Delta, Kappa, and Nociceptin receptor [243]. When aiming for 
cardioprotection, the delta receptor seems the most logical target as these receptors are 
found in the human heart. The delta receptor responds best to the endogenous peptide 
enkephalin, but can also be stimulated by β-endorphins [244]. Interestingly, β-endorphins 
are released during (intense) exercise and, therefore, may represent a logical target in 
(exercise) preconditioning. Moreover, acute intravenous infusion of β-endorphins are also 
associated with improved left ventricular function and reduced systemic vascular resistance 
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in patients with mild to moderate chronic heart failure [245]. Although evidence is still small, 
β-endorphin release may represent an important target to explain preconditioning. 
In an attempt to investigate whether exercise would lead to preconditioning in vivo, in 
chapter 8, we investigated the effect of two different modalities of exercise on brachial 
artery dysfunction. In this study, we revealed some interesting findings. First, high-intensity 
interval exercise successfully prevented the brachial artery from vascular injury after an IR-
stimulus, while moderate intensity exercise exerted no effect at all. Second, the observed 
protective effect of high-intensity exercise proved to function systemically, as brachial artery 
dysfunction was prevented by doing leg exercise.  
 
High intensity interval exercise 
In chapter 8 we discussed the ability of high-intensity interval exercise in preventing brachial 
artery damage. We found that moderate intensity exercise did not exert similar beneficial 
effects. This finding is important for several reasons. First, it clearly shows the ability of high-
intensity interval exercise to prevent brachial artery dysfunction after a longer duration of 
oxygen shortage. As exercise is a standard prescription in many patients with cardiovascular 
disease in the Netherlands, future research should focus on the ability of different types of 
exercise to prevent IR-injury. It could be an extra goal, in addition to goals as improving 
physical fitness and improving functional ability.  
The observation that different types of exercise, although time– and workload-matched, 
exert different effects is important. Given the significant body of evidence regarding the 
strong and potent beneficial effects of exercise in improving health and in the prevention of 
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the development of chronic diseases, it is remarkable to notice that many of the 
mechanisms that explain this effect are poorly understood. As stated in chapter 2, we can 
only explain up to 60% of the beneficial effects provided by exercise [31].  
 
Duration or intensity? 
Although it was not the goal of this thesis to determine the effects of different types of 
exercise for a longer period, it is interesting to speculate whether to use endurance training 
or high-intensity interval training in daily live. For endurance training, it is suggested that the 
optimal training program consists of both high-intensity (short-duration) exercise training 
and low-intensity (high-volume) exercise training [246]. Both types of training exert different 
effects, but to date, several aspects are unclear how to optimize these components in order 
to achieve optimal exercise performance in well-trained athletes. High-intensity interval 
exercise consists of repeated, relatively short bouts of high-intensity exercise interspersed 
with recovery periods [247]. Potentially, not only endurance athletes could benefit from 
high-intensity interval exercise, but also individuals who are seeking alternatives compared 
to traditional forms of exercise for improving health. Interestingly, the last decade, 
increasing evidence suggests that low-volume, high-intensity interval exercise  may 
represent a time-efficient strategy to induce health benefits that are normally only 
associated with endurance training [248]. Moreover, some evidence even suggests that high-
intensity interval exercise  is perceived as more enjoyable in healthy man [249], but also in 
overweight and obese individuals [250]. Moreover, possibly because high-intensity interval 
exercise  is perceived as more enjoyable, overall adherence is suggested to be better than 
traditional moderate in training in for example subjects with prediabetes [251]. 
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Furthermore, adherence has also found to be promising in cardiac rehabilitation [252]. 
Nonetheless, it is important to emphasize that no previous study provided strong evidence 
that high-intensity interval exercise  leads to better adherence than traditional forms of 
exercise. 
 
Is high-intensity interval exercise  superior in patients with chronic disease? 
High-intensity interval exercise is suggested to be a good alternative for traditional 
endurance training performed at moderate intensity, especially in specific type of patients 
who are expected to present with superior health effects compared to regular endurance 
training. One of the most cited studies in this area is the study performed by Wisloff and 
colleagues [99]. In summary, it was founds that high-intensity interval exercise  led to an 
higher increase in physical fitness, vascular function and even left ventricular ejection 
fraction compared to moderate exercise training in a group with heart failure [99]. In 
support of these results, others found that high-intensity interval exercise  has the ability to 
improve insulin sensitivity and glycaemic control in patients diagnosed with type 2 diabetes 
[253] and in obese man [254]..   
While high-intensity interval exercise is mostly described as being superior to moderate 
intensity training, some recent papers investigating the effects of both protocols in cardiac 
rehabilitation found comparable improvements. For example, Cocks et al. [254] did not find 
a superior effect of high-intensity interval exercise in diabetic patients. Although they did not 
find a superior effect, they concluded that high-intensity interval exercise is more time 
efficient and therefore represents a nice alternative. Another example originates from a 
large multicentre trial, in which high-intensity interval exercise  was investigated and 
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compared with moderate intensity training in patients with coronary artery disease. In 
contrast to Wisloff et al [99], similar improvements were found in exercise capacity and 
endothelial function [255]. These results were also found by others, who adopted the same 
exercise training protocols in patients with coronary artery disease [256]. Based on these 
results, one could argue that differences between the studies may be explained by 
differences in the selected patient population. However, from a recent study from the 
Department of Physiology at the Radboud University Medical Center in heart failure patients 
also revealed no differences between both exercise training protocols [257]. Possibly, and 
somewhat driven by the observation of large inter-individual differences in improvement 
after exercise training, it is speculated that treatment should be more individualised. In this 
line, inter-individual differences may contribute to differences in responses to different 
types of exercise training between individuals.  
In conclusion, current evidence suggests that high-intensity interval exercise is a safe [258], 
enjoyable and time-effective way to perform exercise. However, more research is needed to 
specify the exact effects in different type of groups, but also aim to better understand why 
this type of exercise may lead to superior effects compared to traditional forms of exercise 
training. Moreover, as evidence is improving, one should carefully consider whether current 
guidelines regarding the total amount of exercise are still up-to-date, and maybe it is time to 
give intensity a more prominent share, next to the duration of physical activity.  
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Conclusion 
In this thesis, we have tested IPC in various circumstances, using different subjects, with  
diverse objectives. In addition we have tested whether exercise might have similar beneficial 
outcomes. We have shown that IPC is a very promising intervention, but has also some clear 
restrictions, as for example seen in some specific groups. The contents of this thesis  
contribute to further understand this complicated phenomenon.  
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